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IMMUNOREACTIVITY OF ANTI PZP ANTIBODIES FROM THE SERUM OF SPAYVAC 




 Immunocontraception with the porcine zona pellucida (pZP) antigen is a well-published 
means of wild horse contraception. There are three pZP vaccines currently proposed for use in 
horses, Zonastat-H®, PZP-22, and SpayVac®. Despite abundant research concerning the safety 
and contraceptive efficacy of pZP vaccines in numerous species, the contraceptive mechanisms 
of the pZP antigen remain unclear and have not been investigated thoroughly for SpayVac. We 
investigated the immunoreactivity of anti pZP antibodies from the serum of SpayVac vaccinated 
mares to equine zona protein using Western blot and immunohistochemical techniques. These 
techniques were first applied using a bovine model because bovine oocytes are more easily 
obtained in large quantities relative to equine oocytes. Once the procedure was validated, equine 
samples were utilized. Western blot analysis revealed immunoreactivity of anti pZP antibodies 
that were produced in response to SpayVac vaccination to protein isolated from mature equine 
oocytes, equine zona pellucidae, equine follicular tissue, and equine ovarian stromal tissue. 
Immunohistochemical analysis identified the location of binding of anti pZP antibodies to the 
zona pellucida of mature oocytes isolated from Graafian follicles as well as the zona pellucida of 
immature oocytes in ovarian tissue. Western blot and immunohistochemical analyses also 
indicate high specificity of anti pZP antibodies for equine zona protein and predominant affinity 
for zona protein 3. Collectively, results suggest a model where anti pZP antibodies produced in 
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response to SpayVac vaccination are immunoreactive to equine zona protein in vitro. If available 
in the follicular fluid and able to permeate the ovary following SpayVac vaccination, anti pZP 
antibodies may act on not only mature oocytes, but also oocytes of growing follicles in vivo.  
The results of this study lend insight into the infertility observed following SpayVac vaccination, 
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In 1971, wild horses became federally protected under the Wild Free-Roaming Horses 
and Burros Act. The Bureau of Land Management (BLM) was tasked with the protection, 
management, and control of wild horses on BLM managed federal lands in accordance with this 
law (92 Public Law 195). Provided this protection, in combination with a lack of natural 
predators, many wild horse populations began to increase rapidly. Current annual growth rates 
are recognized to range from 10-25% (Eberhardt et al. 1982, Berger 1986, Wolfe 1986, Garrott 
et al. 1991, Greger and Romney 1999, Goodloe et al. 2000, Roelle et al. 2010) while habitats 
remain constant in size and limited in forage availability. These horse populations are therefore 
faced with a finite supply of resources that is unable to sustain increasing herd sizes. In response 
to this, BLM removes thousands of horses annually and places them into their National Adopt-
A-Horse or Burro Program to avoid issues of overpopulation (GAO 2008). When adoption 
demand does not balance removals, the remaining horses are transferred to holding facilities 
where they are fed and cared for by the government (NRC 2013). 
As of 2013, BLM manages approximately 34,000 free-roaming feral horses across 10 
western states and an additional 47,800 captive feral horses in government funded holding 
facilities. In 2013, the costs to feed and care for horses in holding facilities accounted for more 
than half of the BLM’s annual appropriations for the Wild Horse and Burro Program (NRC 
2013). Unless management strategy adjustments are made, the costs of holding animals in long-
term facilities will continue to overwhelm the program (GAO 2008, Garrott and Oli 2013). Since 
wild horse populations can double every four years (Garrott and Oli 2013), and the continued 
removal of horses will only perpetuate the issue (Garrott and Oli 2013, NRC 2013), relying on a 
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gather-removal program is no longer a viable option (NRC 2013). Researchers have thus 
investigated other methods of population growth suppression. 
Research on population control techniques has largely focused on suppressing female 
fertility, particularly through the use of immunocontraceptive vaccines. While there are two 
antigens actively being studied, gonadotropin releasing hormone (GnRH) and porcine zona 
pellucida (pZP), the NRC declared in their 2013 report that immunocontraception with pZP may 
be the more favorable option (NRC 2013). Porcine zona pellucida is an antigen harvested from 
the zona pellucida of porcine oocytes. When incorporated into a vaccine, combined with an 
adjuvant, and injected intramuscularly into another species, the pZP antigen has been shown to 
stimulate an immune response resulting in infertility (Sacco 1977, Liu et al. 1989, Ransom et al. 
2011, Bechert 2013). Despite numerous efficacy studies in multiple species, the mechanisms by 
which the pZP antigen acts to inhibit fertility are not thoroughly understood. When injected, the 
pZP antigen induces an immune reaction that can be measured by serum antibody titers. These 
antibodies are thought to bind zona proteins on ovulated oocytes, thereby inhibiting sperm 
binding and penetration (Sacco 1977, Liu et al. 1989, Kirkpatrick et al. 1990). Since the zona 
pellucida is thought to play a critical role in fertilization and early embryogenesis (Wolgemuth et 
al. 1984, Prasad et al. 2000), it is an optimal target for fertility control research. 
The use and efficacy of pZP vaccines was first investigated in the early 1980s in 
mammals including dogs (Mahi-Brown et al. 1985), rabbits (Wood et al. 1981), and baboons 
(Dunbar et al. 1989). The promising contraceptive results from these studies prompted research 
on its use in horses. Liu et al. (1989) was the first to demonstrate that an aqueous pZP vaccine 
may be a viable contraceptive agent to control wild horse populations through a study in captive, 
feral mares. Kirkpatrick et al. (1990, 1992) further investigated the use of this vaccine, now 
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known as ZonaStat-H®, in a herd of free-roaming horses inhabiting Assateague Island, 
Maryland.  In the two decades that followed, a succession of studies investigated delivery 
methods (Kirkpatrick et al. 1990, Willis et al. 1994), duration of effect (Turner et al. 2002, 2007, 
2008, Ransom et al. 2011), effect on behavior (Nunez et al. 2009, Nunez et al. 2010, Ransom et 
al. 2010), and return to fertility (Kirkpatrick et al. 1992, Ransom et al. 2013). Researchers also 
began investigating new formulations of pZP vaccines that promised longer duration of effect 
than the original aqueous formulation. Turner et al. (2007) tested the efficacy of a presumptive 2-
year pZP vaccine, known as PZP-22 (Turner et al. 2007), and SpayVac® (Immunovaccine Inc., 
Halifax, Nova Scotia, Canada) emerged as a long-lasting, single injection alternative to the 
traditional pZP vaccines in seals (Brown et al 1997) and deer (Hernandez et al. 2006, Locke et al. 
2007). SpayVac has been recently reported for use in horses (Killian et al. 2004, Bechert et al. 
2013), but the contraceptive mechanism of the vaccine is not well documented in published 
literature.  
While pZP vaccines all incorporate the pZP antigen, they are not a homogenous set of 
compounds. Since each vaccine has a slightly different method of preparation and antigen 
isolation, levels of purity between the vaccines may differ. This could account for variability in 
efficacy, duration of effect, and return to fertility between the vaccines (Miller et al. 2009, NRC 
2013). Likewise, individual differences in immunity between mares vaccinated with the pZP 
antigen leads to variations in antibody titer level and efficacy. 
Despite many studies investigating the use of pZP vaccines, the contraceptive 
mechanisms remain unclear. While researchers have investigated serum anti pZP titer levels 
(Willis et al. 1994, Turner et al. 1996), estrogen and progesterone profiles (Kirkpatrick et al. 
1992, Killian et al. 2008), and even ovarian function (Mahi-Brown et al. 1981, Skinner et al. 
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1984, Dunbar et al. 1989, Bechert 2013) as a result of pZP vaccination, few studies have focused 
on SpayVac. Likewise, varying levels of purity, and thus efficacy, among the vaccines may be 
indicative of slight differences in the mechanism of action between the compounds. We tested 
the hypothesis that anti pZP antibodies produced in response to SpayVac vaccination are 
immunoreactive to equine zona protein to better understand the contraceptive mechanisms 
resulting from SpayVac vaccination.  The objectives of this study were to (1) develop and use a 
Western blot assay to determine whether vaccination of wild horse mares with SpayVac results 
in the production of antibodies immunoreactive to equine zona protein, and (2) identify location 
of binding of antibodies from the serum of SpayVac vaccinated mares to equine oocytes and 




















Population Growth Suppression Research 
 In 1971, the U.S. Congress enacted the Wild Free-Roaming Horses and Burros Act, 
which charged the Bureau of Land Management (BLM) with the protection, management and 
control of free-roaming horses and burros on BLM managed federal lands (92 Public Law 195). 
BLM currently manages approximately 34,000 free-roaming feral horses on public lands and an 
additional 47,800 horses in long- and short- term holding facilities. With holding facility 
capacity nearly at its limit, and wild horse populations capable of growing 10-25% annually 
(Eberhardt et al. 1982, Berger 1986, Wolfe 1986, Garrott et al. 1991, Greger and Romney 1999, 
Goodloe et al. 2000, Roelle et al. 2010), relying on a gather-removal program is no longer a 
viable option (GAO 2008).  Researchers have thus investigated other methods of population 
control.  
 Such research has largely focused on suppressing female fertility, particularly through the 
use of surgical sterilization (NRC 2013), intrauterine implants (Daels and Hughes 1995, Killian 
et al. 2004) and immunocontraception (Kirkpatrick et al. 2011). While the first two methods are 
less favorable due to their invasive nature, the latter is associated with ease of administration and 
nominal discomfort to the animal during application. Ideal characteristics of a potential fertility 
control method are ease of delivery, high efficacy, prolonged duration of effect, and minimal 
physiological and behavioral side effects (NRC 2013). Immunocontraception with porcine zona 
pellucida (pZP) vaccines may be the most promising option at present as it fulfills these criteria 
(NRC 2013).   
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Surgical sterilization procedures, such as ovariectomy and ovariohysterectomy, are 
commonly practiced in domestic species and offer complete, irreversible infertility. These 
procedures, however, are seldom applied to free-ranging species since accessing the female 
reproductive tract in a field setting is difficult and often carries the risk of post-operative 
complications, such as septic peritonitis (Freeman et al. 2007). The possibility that these 
procedures may be followed by prolonged bleeding or peritonitis makes them inadvisable for 
field application (NRC 2013).  Additionally, surgeries such as these typically require movement 
restriction and monitoring, making them logistically difficult to apply to a free-ranging species 
(NRC 2013).  
Two studies of note investigated the use of intrauterine devices (IUDs) in horses as a 
method of fertility control. Daels and Hughes (1995) fitted 6 domestic mares with silastic O-
ring-shaped IUDs to investigate the contraceptive efficacy. The IUDs were in place for just less 
than 1 year and 100% efficacy was achieved during this time period. After removal of the IUDs 
in early spring, each mare was able to return to fertility, conceive, and deliver a normal foal at 
term. Uterine cytology and histopathology indicated that the IUD caused a mild inflammation of 
the uterus sufficient to interfere with fertility while not permanently affecting reproductive health 
(Daels and Hughes 1995). Killian et al. (2004) evaluated three different IUDs in pony mares for 
ease of placement, retention and efficacy. The results of this preliminary study in ponies led the 
authors to implant 15 captive, feral mares with a copper containing IUD (Killian et al. 2004 and 
2008). After four years of study, rates of contraception for years 1, 2, 3, and 4 respectively were 
80%, 29%, 14%, and 0%. Ultrasound analysis confirmed that the pregnancies of IUD-implanted 
mares were due to a loss of the IUD itself rather than a failure of the device. Likewise, the 
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authors note IUD retention may be a function of uterine size, as pony mares implanted with 
IUDs had higher retention and contraception rates than larger, feral mares (Killian et al. 2008).  
While IUDs are not as invasive as surgical sterilization procedures, implantation of the 
IUD requires capture of the animal, restraint, and transcervical insertion of the device. Killian et 
al. (2008) described this process as cumbersome and time consuming, even while using chemical 
restraint for IUD placement. The device itself may provoke undue uterine inflammation and 
further research concerning loss rates of the IUDs is needed before widespread use (NRC 2013).  
One of the most encouraging areas of fertility control research focuses on 
immunocontraception. Immunocontraceptive vaccines are advantageous as they can be remotely 
delivered, are noninvasive, and offer high efficacy with few adverse side effects (Kirkpatrick et 
al. 2011, NRC 2013). These vaccines use the animal’s own immune system to interfere with a 
critical reproductive event (Miller et al. 2008, Gray et al. 2010). Likewise, since the vaccine is 
specific to a chosen tissue or biochemical, it can target specific hormones or tissues within the 
animal while not causing harm to other tissues (Barber and Fayrer-Hosken 2000). The most 
studied immunocontraceptive vaccines are the gonadotropin-releasing hormone (GnRH) vaccine, 
GonaConTM, and the three formulations of porcine zona pellucida (pZP) incorporating vaccines: 
Zonastat-H®, pZP-22 and SpayVac® (NRC 2013). 
 
Immunocontraception with Gonadotropin Releasing Hormone (GnRH) Vaccines 
GnRH is a trophic peptide hormone that is secreted in a pulsatile form from neurons in 
the preoptic area of the hypothalamus. It stimulates the release of follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH) from the anterior pituitary gland (Irvine and Alexander 
2005). Briefly, LH and FSH act on cells of the developing follicle to cause cellular proliferation, 
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follicular growth, ovarian estrogen and progesterone production, and ovulation (Alexander and 
Irvine 2005). When a GnRH peptide is conjugated to a large foreign protein, combined with an 
adjuvant, and injected into an animal an immune response is developed which ultimately results 
in infertility (Miller et al. 2008). Antibodies produced in response to vaccination bind to 
endogenous GnRH, preventing it from diffusing into the anterior pituitary from the blood (Gray 
et al. 2010). Infertility is thus achieved by limiting the availability of endogenous GnRH to the 
anterior pituitary gland, thereby reducing the secretion of both FSH and LH, culminating in an 
inhibition of ovulation (Miller et al. 2008, Gray et al. 2010). 
Two formulations of GonaCon have been reported with varying levels of efficacy. 
GonaCon-KLH, where the GnRH peptide has been conjugated to a keyhole limpet hemocyanin 
protein, is typically less effective than GonaCon-B, where a blue mollusk protein is used in the 
conjugation (Killian et al. 2008, Miller et al. 2008). While these GnRH vaccines have proven 
effective in many species, including deer (Miller et al. 2000, Gionfriddo et al. 2011), wild boar 
(Killian et al. 2003, Miller et al. 2004a), bison (Miller et al. 2004b), and feral cats (Levy et al. 
2004), there are only a few published studies of the use of GonaCon as a contraceptive agent in 
the horse. Killian et al. (2008) evaluated the multiyear contraceptive efficacy of GonaCon-KLH 
in captive, feral mares. Rates of contraception for years 1, 2, 3, and 4 respectively were 94%, 
60%, 60%, and 40% (Killian et al. 2008). Gray et al. (2010) observed slightly lower 
contraception rates in free-roaming feral horses following immunocontraception with GonaCon-
B; 39%, 42% and 31% respectively for years 1, 2 and 3 post treatment. Baker et al. (2013) also 
investigated the effects of GonaCon-B on a herd of free roaming horses. The estimated foaling 
rate in the first year following treatment was 48% for treated mares compared to 75% for control 
mares (Baker et al. 2013). Although these results contradict the general opinion that GonaCon-B 
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is more effective than GonaCon-KLH, the authors attribute this discrepancy to their use of a 
more conservative method of fertility estimation as well as potential differences in body 
condition between captive and free-ranging mares (Gray et al. 2010). Gray et al. (2010) 
monitored mares at least weekly and supplemented visual observations with fecal steroid 
hormone analysis.  The authors indicate that this intense monitoring allowed them to observe 
events which may otherwise be missed when only assessing fertility as a function of foal 
production, such as whether a mare aborted a fetus early or lost a foal shortly after birth (Gray et 
al. 2010).   
 
Immunocontraception with Porcine Zona Pellucida (pZP) Vaccines 
 Although GnRH vaccines were found to be an effective means of immunocontraception 
for the horse (Miller et al. 2008, Gray et al. 2010), studies concerning their duration of effect and 
efficacy in horses are rare. Likewise, GnRH vaccines are generally considered to be less 
efficacious in the short-term than pZP vaccines (NRC 2013). Alternatively, 
immunocontraception with pZP has been extensively tested and documented in literature, offers 
high contraceptive efficacy, and is more predictable as a contraceptive agent (Kirkpatrick et al. 
2011, NRC 2013).  
The zona pellucida is a unique glycoprotein matrix that surrounds the mammalian oocyte. 
It is thought that zona proteins play a critical role in folliculogenesis, fertilization, and early 
embryogenesis (Wolgemuth et al. 1984, Prasad et al. 2000). The zona pellucida’s assumed role 
in fertilization makes it an expected target for fertility control research. Specifically, when zona 
proteins harvested in one species are used as an antigen in another, they have been shown to 
stimulate an immune response, measured by serum antibody titers, that results in infertility 
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(Sacco 1977, Liu et al. 1989). Despite efficacy studies in multiple species, the mechanism by 
which the pZP antigen acts to inhibit fertility is not thoroughly understood. When injected, pZP 
vaccines induce an immune reaction in which anti pZP antibodies are generated. These 
antibodies are thought to bind zona pellucida proteins on mature oocytes, thereby interfering 
with sperm binding and penetration (Sacco 1977, Liu et al. 1989, Kirkpatrick et al. 1990). Other 
studies demonstrated follicular dysgenesis in the rabbit (Skinner et al. 1984) and mare 
(Kirkpatrick et al. 1995) following vaccination, including diminished ovulatory ability 
(Kirkpatrick et al. 1995), absence of mature oocytes and follicles (Skinner et al. 1984), and a 
decline in ovarian estrogen secretion (Kirkpatrick et al. 1995). These results suggest an effect of 
pZP vaccination on ovarian function in addition to an interruption at the level of sperm binding 
sites. Paterson and Aitken (1990) agree with both of these hypotheses and suggest that anti pZP 
antibodies can cause infertility by disturbing both folliculogenesis and sperm-egg interactions. It 
is well documented that these effects occur following vaccination, regardless of which stage of 
the reproductive process pZP vaccines target. 
The use and efficacy of pZP vaccines was first investigated in the early 1980s in 
mammals including dogs (Mahi-Brown et al. 1985), rabbits (Wood et al. 1981), and baboons 
(Dunbar et al. 1989).  The promising contraceptive results from these studies prompted further 
research on its use in mares (Liu et al. 1989, Kirkpatrick et al. 1990, Willis et al. 1994). In recent 
decades, pZP vaccines have grown in popularity with wild horse managers due to their relative 
ease of application, lack of significant side-effects, and proven temporary efficacy (Ransom et al. 
2011). 
Liu et al. (1989) was the first to document the use of an aqueous pZP vaccine, later to 
become known as Zonastat-H, in mares. Fourteen fertile mares were immunized with a series of 
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four aqueous pZP intramuscular injections and their immune responses were measured by an 
enzyme-linked immunosorbent assay (ELISA). Inhibition of fertility occurred in 12 of the 14 
mares (86%) and persisted for a minimum of seven months. While only a preliminary study, Liu 
et al. (1989) demonstrated that pZP vaccination may be a viable contraceptive option to control 
wild horse populations. The authors suggested the need for more studies to investigate the effects 
on long-term fertility and improve the method of administration (Liu et al. 1989). 
Kirkpatrick et al. (1990) further explored this aqueous pZP vaccine, known as ZonaStat-
H, by documenting its use in a free-roaming herd of feral horses inhabiting Assateague Island 
National Seashore, Maryland. In 1988, 26 mares were inoculated with a series of two aqueous 
pZP injections, the majority of which were delivered by dart from 25 to 30 meters distance. 
Eighteen of the original 26 mares received a third injection 2-4 weeks after the second. Of the 
original 26 treated mares, 14 were pregnant at the time of inoculation and all 14 produced normal 
healthy foals in the spring of 1988, verifying a lack of observed effect on existing pregnancies. 
By August 1989, one year after vaccination, only 1 of the 26 mares foaled. This study was the 
first to document successful fertility inhibition among free-roaming horses by means of remotely 
delivered immunocontraception. The authors concluded that remote inoculation of feral mares 
with this aqueous pZP vaccine was an effective means of fertility inhibition (Kirkpatrick et al. 
1990). 
Kirkpatrick et al. (1992) continued to monitor this herd of mares on Assateague Island in 
order to determine the long-term effects of ZonaStat-H on ovarian function and contraceptive 
efficacy. Ten free-roaming mares that were initially inoculated in 1988 with aqueous pZP 
received 2 additional annual boosters in 1989 and 1990. Following the third annual pZP 
inoculation, ovarian function was monitored for 51 days during the breeding season by means of 
12 
 
urinary estrone conjugates and nonspecific progesterone metabolites. One treated mare was 
pregnant as a result of conception in 1989 and none of the ten treated mares became pregnant in 
1990. Four of the treated mares revealed no evidence of ovulation and displayed significantly 
depressed urinary estrogen concentrations. Observations indicate that a third consecutive annual 
pZP booster is more than 90% effective in inhibiting pregnancy, but that three consecutive years 
of treatment may interfere with normal ovarian function (Kirkpatrick et al. 1992).  
In the years to follow, a succession of studies investigated new remote-delivery methods 
(Willis et al. 1994), duration of efficacy (Turner et al. 2002, 2007, 2008, Ransom et al. 2011), 
behavioral effects as a result of contraception (Nunez et al. 2009, Nunez et al. 2010, Ransom et 
al. 2010), and return to fertility (Kirkpatrick et al. 1992, Ransom et al. 2013). Likewise, 
researchers began investigating formulations of the pZP antigen that promised multiyear 
efficacy. Turner et al. (2007) tested the effectiveness of a targeted 2-year pZP vaccine that 
incorporated a controlled-release adjuvant component in feral mares. The vaccine, later to 
become known as PZP-22, consisted of two components: a primer dose of aqueous pZP and a 
booster dose in the form of controlled-release polymer pellets. The study by Turner et al. (2007) 
reported high efficacy for 2 years post treatment with some residual contraceptive effect in year 
3. Similarly, SpayVac (Immunovaccine Inc., Halifax, Nova Scotia, Canada) emerged as a long-
lasting, single injection pZP vaccine in seals (Brown et al. 1997) and deer (Hernandez et al. 
2006, Locke et al. 2007). SpayVac has been recently reported for use in horses (Killian et al. 
2004, Bechert et al. 2013), but the contraceptive mechanism of the vaccine is not well 
documented in published literature. 
Efficacy studies have demonstrated that heteroimmunization with the pZP antigen, that 
is, using porcine zona proteins as a vaccine for another species, not only effectively induces 
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infertility, but also results in follicular dysgenesis in some cases (Mahi-Brown et al. 1985, 
Dunbar et al. 1989, Paterson and Aitken 1990, Killian et al. 2008). These results raise the 
question of how the pZP antigen, or the antibodies produced in response to vaccination, elicits 
these responses. Previous studies have determined the equine zona pellucida to be composed of 
the zona protein families ZP1, ZP2, ZP3 and ZP4 that have antigenic properties similar to those 
found in other species, such as the pig (Liu and Shivers 1982, Miller et al. 1992, Goudet et al. 
2008). When pZP is prepared, the entire porcine zona pellucida is homogenized; resulting in a 
vaccine composed of all zona protein families. Wassarman (1988) indicated ZP3 to be the most 
prominent component of the porcine zona pellucida, representing as much as 70-80% of total 
protein content. It therefore follows that pZP vaccines are likely composed of a larger proportion 
of ZP3 than the other zona proteins. Since ZP3 is primarily implicated in fertilization events, 
pZP’s possible effect on sperm binding to and penetration of the equine zona pellucida is of 
particular importance. However, with the vaccine being a compilation of all zona protein 
families, a possible effect on zona pellucida structure and follicular development is also of 
interest. 
 
Porcine Zona Pellucida (pZP) Vaccine Preparations 
While ZonaStat-H, PZP-22 and SpayVac incorporate the pZP antigen, the three vaccines 
are not a homogenous set of compounds. Rather, differences in antigen preparation result in 
variations in purity and protein content (NRC 2013). It is likely that the SpayVac formulation 
contains more non-zona pellucida proteins than the method described by Liu et al. (1989). Miller 
et al. (2009) suggests that these differences in antigen preparation may account for the variability 
in efficacy levels observed among vaccines.  Likewise, the methods of pZP antigen isolation 
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described in published literature simply cite that porcine ovaries were obtained from local 
slaughter houses for antigen isolation and never mention the age or reproductive status of the 
sows the ovaries were harvested from (Yurewicz et al. 1983, Liu et al. 1989). These are 
important confounding factors that can contribute to the complex nature of the pZP antigen 
among vaccine preparations.   
ZonaStat-H is a two-injection, aqueous formulation of pZP that is registered with the 
Environmental Protection Agency (EPA) as a mammalian contraceptive. ZonaStat-H includes a 
primer of aqueous pZP emulsified in Freund’s Complete Adjuvant, Modified and a booster of 
aqueous pZP in Freund’s Incomplete Adjuvant, Modified given 2 to 4 weeks later (Kirkpatrick et 
al. 1990). The primer is prepared by emulsifying 0.5cc aqueous pZP (65μg pZP suspended in 
0.5cc phosphate buffered saline; PBS) with 0.5cc Freund’s Complete Adjuvant (Kirkpatrick et 
al. 1990).  The booster injection also contains 0.5cc aqueous pZP, but it is emulsified in Freund’s 
Incomplete Adjuvant (Kirkpatrick et al. 1990). The preparation of aqueous pZP for this vaccine 
is outlined by Liu et al (1989) and details slicing porcine ovaries to release oocytes from 
surrounding tissues prior to a series of passages through filters of decreasing pore size. Trapped 
oocytes are further homogenized and the resulting zona pellucidae are trapped on a 48µm screen. 
The zona pellucidae are washed in PBS and heat solubilized at 70° Celsius for 30 minutes in 
PBS. The supernatant is finally concentrated through ultrafiltration and stored as an aqueous 
solution. ZonaStat-H targets one year of contraceptive efficacy (Liu et al. 1989).  
PZP-22 also involves two injections, a liquid primer followed by a booster in the form of 
three heat-extruded pellets. The liquid primer is made by emulsifying 65μg aqueous pZP in PBS, 
prepared as detailed above for ZonaStat-H, with 0.5 cc Freund’s Complete Adjuvant.  The 
booster pellets incorporate lyophilized pZP and QS-21, a water-soluble saponin adjuvant, 
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matrixed in homogenous lactide and glycolide polymers (Turner et al. 2007).  The pellets are 
designed to act in a time-release fashion, where the contents of the first pellet are released 1 
month, the second released 3 months, and the final released 12 months, after initial inoculation.  
The first pellet incorporates 70μg pZP with 175μg QS-21, the second pellet incorporates 90μg 
pZP with 200μg QS-21, and the third pellet incorporates 250μg pZP with 500μg QS-22 (Turner 
et al. 2007). This time-release delivery method targets 22 months of efficacy (Turner et al 2007).  
Finally, SpayVac is a single injection formulation in which the pZP antigen is 
encapsulated in liposomes for targeted multi-year contraceptive efficacy. Alternative to the 
preparation of aqueous pZP detailed above by Lui et al. (1989), Yurewicz et al. (1983) details a 
preparation where frozen-thawed whole porcine ovaries are homogenized in Tris-zona buffer and 
zona-encased oocytes are recovered by a succession of passages of the homogenate through 
nylon screens of decreasing pore sizes. Oocytes are trapped on a 100μm screen, collected by 
washing into Tris-zona buffer, and homogenized further. The resulting zona pellucidae are 
trapped on a 50µm screen, heat solubilized at 73° Celsius for 20 minutes, and centrifuged at 
27,000 x g for 15 minutes. The supernatant is finally concentrated through ultrafiltration and 
stored as an aqueous solution. An aliquot of 100μg aqueous pZP is encapsulated in liposomes 
and mixed with Freund’s Complete Adjuvant, Modified  (Yurewicz et al. 1983, Brown et al 
1997). 
 
Immune Response to Vaccination 
 The immune system has evolved as a critical defense mechanism against the risks 
imposed by infectious microorganisms. While immunity has many facets, two main 
immunological branches are required for proper immune response. These are the innate 
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immunity and adaptive immunity (Hoebe et al. 2004). The innate immune response is 
responsible for the rapid release of inflammatory cytokines and activation of antigen-presenting 
cells as the first line of defense against a foreign microbe. In contrast, adaptive immunity is much 
slower in nature and utilizes a very specific mechanism of selection and clonal expansion to 
recognize antigens and provide long-lasting immunological memory (Pashine et al. 2005). These 
two branches of the immune system perform very distinct functions and their interaction and 
coexistence is critical for proper immune system function (Hoebe et al. 2004). 
 The innate immune response incorporates a wide variety of pattern-recognition receptors 
to recognize pathogen associated molecular patterns (PAMPs) and activate the release of 
inflammatory mediators (Pashine et al. 2005). Pattern-recognition receptors are differentially 
expressed on a variety of immune cells, including neutrophils, B cells, natural killer cells and 
macrophages (Pashine et al. 2005). When the receptor recognizes a PAMP, it activates the 
secretion of cytokines and chemokines from the immune cells it is expressed on, recruits 
additional immune cells to the site of infliction, and induces phagocytosis of the antigen by 
antigen-presenting cells (Hoebe et al. 2004). This culminates in an inflammatory response that 
will influence the establishment of the adaptive immune response.  
 Once immune cells have phagocytized the antigen, rendering them activated, immune 
cells migrate to the lymph nodes where T-cells of the adaptive immune system recognize the 
antigen and undergo clonal expansion (Pashine et al. 2005). T cells interact with and activate B 
cells, which differentiate into plasma and memory cells (Pashine et al. 2005). Plasma cells exit 
the lymph nodes and secrete antigen specific antibodies, while memory cells are reserved for a 
secondary encounter with the specific antigen (Pashine et al. 2005). In this way, the 
inflammatory environment established by the innate immune response serves to condition the 
17 
 
site of infliction for adaptive immunity initiation. Hoebe et al. (2004) further indicates a 
dependency of the adaptive immune response on antigen presentation by the innate immune 
response.  
 This is the manner by which an immune response ensues when an animal is vaccinated 
with an antigen. Innate immunity stimulates an inflammatory response, antigen-presenting cells 
condition adaptive immunity, and antigen-specific antibodies are produced (Pashine et al. 2005). 
When an antigen is presented to the immune system for the first time, no memory cells exist to 
guide the immune response. In this case, stimulation of the innate immune system is critical to 
elicit an initial immune response to the antigen. Inclusion of immunological agents or 
potentiators, such as adjuvants, in the vaccine is thus commonly used to facilitate this process.  
Adjuvants are immunological agents that improve vaccine efficacy. When incorporated 
into a vaccine, adjuvants have been shown to enhance and modulate the immune response in 
such a way as to reduce the amount of antigen and number of immunizations required to achieve 
a high rate of efficacy (Aguilar and Rodriguez 2007). Adjuvants therefore work to generate long-
lasting antigen depots in order to prolong the presentation of the antigen to the immune system 
(Reed et al. 2008). As indicated earlier, the immune response is triggered by the recognition of 
PAMPs by pattern-recognition receptors on immune cells. For this reason, PAMPs are often used 
as the basis for many adjuvants (Reed et al. 2008). Adjuvants also typically incorporate 
cytokines, bacterial toxins and glycolipids to augment the immune response (Reed et al. 2008).  
Water-in-oil emulsions, liposomes, and saponins are three adjuvants that are commonly 
used in conjunction with immunocontraceptive antigens. Water-in-oil emulsions, such as those 
formed with Freund’s Complete and Incomplete Adjuvants, are microdroplets of water, 
stabilized by surfactant in a continuous oil phase (Cox and Coulter 1997). These adjuvants are 
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characterized by their ability to induce an antibody response when emulsified with an antigen 
while remaining immunologically inert in the absence of local irritant (Cox and Coulter 1997). 
Liposomes are single or multilamellar bilayer membrane vesicles that provide a safe means for 
immunomodulators to be incorporated into a vaccine (Cox and Coulter 1997). Saponins, 
including Quil A and QS21, are triterpene glycosides isolated from plants that are directly 
targeted to and efficiently taken up by antigen presenting cells (Reed et al. 2008).  
 
Folliculogenesis and Zona Pellucida Biosynthesis 
Folliculogenesis is an intricate, highly regulated process that is inextricably coupled with 
oogenesis. At birth, the female ovary contains a lifetime’s supply of primordial follicles. Oocytes 
in primordial follicles are arrested in meiotic prophase I and surrounded by a single layer of 
squamous granulosa cells (Pierson 2005). Commencing primarily at puberty in response to 
hormones, and continuing in a cyclic fashion throughout reproductive life, primordial follicles 
are recruited to enter the maturation and differentiation process known as folliculogenesis. 
Primordial follicles first develop into primary follicles. This transition involves differentiation of 
the squamous layer of granulosa cells into a cuboidal epithelium, formation of the zona 
pellucida, and oocyte growth (Richards 1980). A cohort of these primary follicles is further 
selected to develop into antral follicles, characterized by a follicular fluid-filled antrum and the 
differentiation of theca cells. Finally, one dominant follicle matures into a Graafian follicle, 
marked by a dramatic increase in follicular fluid volume, and awaits ovulation (Pierson 2005). 
The oocyte remains in meiotic arrest throughout this process, with resumption of meiosis only 
occurring as a result of the LH surge at ovulation (Richards 1980). 
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During the early stages of folliculogenesis, the zona pellucida is formed between the 
plasma membrane of the mammalian oocyte and surrounding granulosa cells (Pierson 2005). The 
zona pellucida is a unique extracellular matrix composing three or four glycoproteins, depending 
on the species, that are synthesized as an integrated action of both the oocyte and the granulosa 
cells (Wolgemuth et al. 1984, Leveille et al. 1987, Rankin et al. 1996, Blackmore et al. 2004). 
The different glycoproteins, known as zona proteins, share an overall similar architecture around 
a conserved C-terminal zona protein domain, while sequences downstream from this domain are 
much more variable and contribute to the functional differences between each of the proteins 
(Prasad et al. 2000). Zona proteins are generally categorized into four protein families based on 
structure and function similarity. Specifically, zona protein families ZP1, ZP2, and ZP4 are 
thought to be involved in zona pellucida structure whereas ZP3 has a known role in sperm 
binding and penetration (Prasad et al. 2000).  
Furthermore, while zona proteins within a protein family share an overall similar 
structure, they also exhibit heterogeneity due to extensive post-translational modifications. 
Heavy glycosylation and sulfation patterns lend to variances in electrophoretic mobilities and 
carbohydrate moeities among species and between proteins (Dunbar et al. 1994, Prasad et al. 
2000). Likewise, proteolytic cleavage and deglycosylation events have been shown to process 
these large zona glycoproteins into polypeptides of smaller molecular weights. Zona proteins are 
also known to exist as heterodimers, and thus appear to be of increased molecular weight. 
(Wassarman 1988, Prasad et al. 2000) These post-translational modifications complicate the 
ability to accurately identify zona proteins by electrophoresis (Wassarman 1988). For instance, 
Dunbar et al. (1985) published a 2D PAGE gel illustrating the zona protein families of a porcine 
zona pellucida ranging from 6 to 93 kDa. The authors suggest that the protein family appearing 
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in the 6-30 kDa range during 2D PAGE analysis is formed due to proteolytic processing of the 
ZP2 protein family, which would typically appear in the 60-65 kDa range (Dunbar et al. 1995). 
Wassarman (1988) confirmed these results by suggesting that the ZP4 porcine glycoprotein 
appears to have a molecular weight of 15-25 kDA, particularly under reducing conditions. 
Wasserman (1988) continues to define this protein family as being derived from proteolytic 
events and identifies molecular weight differences between glycoproteins and polypeptides of 
the same zona protein family. Additionally, Wasserman (1988) found the porcine zona pellucida 
to be composed of zona protein families in the 68-90, 52-99, 32-55, and 15-25 kDa ranges, 
indicating a broad spectrum of protein weights within and among each zona protein family. 
Meanwhile, Miller et al. (1992) found 3 major zona protein glycoprotein families in the horse 
varying in sizes of 93-120, 73-90, and 45-80 kDa. Collectively, these experiments define and 
explain the broad range of molecular weights observed within zona protein families and among 
species when the zona pellucida is analyzed by gel electrophoresis.  
The zona pellucida ultimately develops into a selectively permeable barrier in the primary 
follicle that is thought to be involved in folliculogenesis, fertilization, and early embryogenesis 
(Wolgemuth et al. 1984, Prasad et al. 2000). Concurrent with the development of the zona 
pellucida, the establishment of gap junctions between neighboring granulosa cells and the oocyte 
permit communication between these cell types. The presence of gap junctions is particularly 
important after the formation of the zona pellucida, which would otherwise serve as a barrier 
limiting diffusion of materials needed for oocyte growth.  Oocyte growth is thus thought to be 
mediated primarily by granulosa cells by way of gap junctions (Prasaad et al. 2000, Eppig et al. 
2002).  Eppig et al. (2002) proposes that this communication is bidirectional, where oocytes 
promote granulosa cell proliferation, differentiation and function while granulosa cells support 
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the growth, development and progression through meiosis of the oocyte. The functional role of 
the zona pellucida in folliculogenesis is less clear. Due to the location of the zona pellucida 
between the oocyte and surrounding granulosa cells, some argue that it plays a direct role in this 
cell-cell communication necessary for folliculogenesis and oocyte maturation (Wolgemuth et al. 
1984, Prasaad et al. 2000). Conversely, others have shown that follicular maturation proceeds as 
normal in the absence of zona matrix (Rankin et al. 1996).  
 
Role of the Zona Pellucida in Fertilization 
 Fertilization is the process by which one spermatozoon interacts with and fuses to an 
ovulated oocyte to form a zygote. At this time, somatic chromosome number is restored and 
development of a new individual is initiated. Fertilization is classically thought to be the 
cumulative result of a number of highly regulated events (Wassarman 1999). These events 
include ovulation, spermatozoa migration into the oviduct, spermatozoa capacitation, binding of 
spermatozoa to the zona pellucida matrix, the acrosome reaction, sperm egg fusion, and finally 
oocyte activation (Wassarman 1999, Okabe 2013).  
At the time of ovulation, an oocyte completes meiosis I and is deposited into the oviduct 
to await fertilization (Richards 1980). Meanwhile, spermatozoa migrate into the female 
reproductive tract and undergo the physiological change known as capacitation (Okabe 2013). 
Capacitation results in the hyperactivation of spermatozoa, which is characterized by a vigorous 
mobility thought to be responsible for the thrusting motion necessary to penetrate the zona 
pellucida (Okabe 2013). In a sequence of events that is unclear, spermatozoa undergo the 
acrosome reaction and bind ZP3 on the zona pellucida of the oocyte (Wassarman 1999, Okabe 
2013). During the acrosome reaction, lytic enzymes are released and zona binding proteins are 
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exposed providing spermatozoa with the ability to penetrate and bind the zona pellucida (Okabe 
2013). Once spermatozoa have bound to and penetrated the zona pellucida, they reach the 
perivitelline space between the oocyte plasma membrane and zona pellucida (Wassarman 1999). 
One spermatozoon fuses with the plasma membrane of the oocyte and releases PLC-zeta, which 
is implicated in the activation of the oocyte and subsequent calcium oscillations (Okabe 2013). 
The oocyte completes the second meiotic cell division and releases cortical granules. Finally, 
ovastacin, which is an enzyme accumulated in the cortical granules, is released, cleaves ZP2 and 
effectively prevents polyspermy (Okabe 2013).  
The classical models of fertilization focus on the ability of sperm to bind the zona 
pellucida and the involvement of the zona pellucida in the acrosome reaction (Okabe 2013). 
Researchers postulate that these two events are both dependent on one another and required for 
fertilization to occur (Okabe 2013). However, recent research involving gene disruption and 
knock-out experiments has questioned the importance of these events in fertilization. 
Spermatozoa from mice with impaired zona binding ability due to either a deficiency in the testis 
specific molecular chaperone PDILT (Tokuhiro et al. 2012) or a knockout in the Adam 1a gene 
(Nishimura et al. 2004) retained their ability to fertilize cumulus-covered oocytes. These studies 
suggest that the ability of spermatozoa to bind the zona pellucida may be dispensable for 
fertilization (Okabe 2013). Likewise, many researchers hypothesize that the acrosome reaction is 
initiated upon contact with the zona pellucida and spermatozoa that have prematurely undergone 
the acrosome reaction prior to contact are unable to fertilize the egg (Bleil and Wassarman 
1983).  Nevertheless, recent studies suggest that the action of penetration through the zona 
matrix, rather than surface binding, induces the acrosome reaction as the researchers were unable 
to observe the acrosome reaction of GFP transgenic spermatozoa upon binding to the zona 
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pellucida (Nakanishi et al. 1999, Baibakov et al. 2007).  Jin et al. (2011) agrees with this and 
suggests that most of the fertilizing spermatozoa are acrosome reacted prior to arriving at the 
zona pellucida in vitro, indicating the acrosome reaction is zona-independent. These studies 
question the importance of the zona-induced acrosome reaction and zona-binding ability in the 
success of fertilization (Okabe 2013).  
Conversely, Rankin et al. (1996) found mice with a genetic defect in the ZP3 gene to be 
infertile. While homozygous mutant ZP3-/- mice had oocyte containing follicles that underwent 
folliculogenesis and ovulation, the oocytes were marked by an absence of the zona pellucida and 
disrupted cumulus-oocyte complex upon ovulation (Rankin et al. 1996). When mated with 
normal males, these mice did not become visibly pregnant and produced no litters (Rankin et al. 
1996). This study suggests a necessity of the zona pellucida for successful in vivo fertilization. 
This is in contrast to the known ability to fertilize zona-free oocytes in vitro (Fulka et al. 1982, 
Rankin et al. 1996). The contradictory nature of these studies implies that the zona pellucida’s 
role in fertilization is not thoroughly understood and the molecular mechanisms underlying 
fertilization remain largely unknown.  
 
Contraceptive Mechanism 
The contraceptive mechanisms of pZP vaccines remain unclear. Many studies have 
investigated serum anti pZP titer levels (Willis et al. 1994, Turner et al. 1996), estrogen and 
progesterone levels (Kirkpatrick et al. 1992, Killian et al. 2008), and even ovarian function 
(Mahi-Brown et al. 1981, Skinner et al 1984, Dunbar et al. 1989, Bechert et al. 2013) following 
vaccination. However the ability of anti pZP antibodies produced in response to SpayVac 
vaccination to recognize equine zona protein has not been thoroughly investigated. One notable 
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exception is a study that used immunohistochemical staining of an equine oocyte to demonstrate 
that antibodies raised in the mare in response to PZP-22 vaccination are able to bind the zona 
proteins of the zona pellucida (Liu et al. 2005). While the study by Liu et al. (2005) lends 
valuable insight into the mechanism of action behind PZP-22 vaccination, variations in purity 
and antigen content among vaccines prevent these results from being directly applicable to 
SpayVac vaccination. As noted by the National Research Council (NRC 2013), it is likely that 
the SpayVac vaccine contains more non-zona pellucida proteins than the other pZP vaccines. 
This may account for antigenic differences between SpayVac and PZP-22 (Miller et al. 2009).  
Since SpayVac is emerging as a longer-lasting alternative to PZP-22, we investigated the 
mechanism of action of SpayVac vaccination by demonstrating the immunoreactivity of 













CHAPTER III: DEVELOPMENT OF AN ASSAY TO TEST THE IMMUNOREACTIVITY OF 
ANTI PZP ANTIBODIES RAISED IN THE MARE IN RESPONSE TO SPAYVAC 





 We developed and verified an assay to test the immunoreactivity of anti porcine zona 
pellucida antibodies raised in the mare in response to SpayVac® vaccination (anti pZP 
antibodies). Initially, bovine oocytes were used as they are more easily obtained in large 
quantities than horse oocytes, and bovine zona proteins share a strong homology to equine zona 
proteins, as verified by the National Library of Medicine Basic Alignment Search Tool 
(BLAST®). BLAST analysis confirmed greater than 75% homology between all sequences of 
zona proteins across the two species. The presence of zona protein 3 (ZP3) and zona protein 4 
(ZP4) was then confirmed in bovine oocytes and zona pellucidae through Western blot analysis. 
Immunoreactivity of serum from a SpayVac vaccinated mare to zona protein was tested by a 
modified Western blot approach in which serum from SpayVac vaccinated and non-vaccinated 
mares was used as the primary antibody. A horseradish peroxidase (HRP) conjugated goat anti 
horse IgG polyclonal antibody was used as the secondary antibody to determine whether anti 
pZP antibodies present in the serum samples of vaccinated mares are capable of binding a 
protein of interest. Similarly, we modified an immunohistochemistry (IHC) protocol to use 
serum as the primary antibody and a HRP conjugated goat anti horse IgG polyclonal antibody as 
the secondary antibody in order to identify the location of binding of anti pZP antibodies to 
whole oocytes. Serum from non-vaccinated mares was used as a control to ensure that the 
antibodies binding the protein samples were a result of SpayVac vaccination. These experiments 
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led to the development of a binding assay that tests whether antibodies present in serum can bind 
to a specific protein of interest.  Results suggest that anti pZP antibodies in the serum of 
SpayVac vaccinated mares are capable of binding protein isolated from whole bovine oocytes 
and bovine zona pellucida.   
 
Materials and Methods 
Samples 
 Bovine ovaries were donated by a local slaughterhouse (JBS Swift & Co, Greeley, CO) to 
the Colorado State University Animal Reproduction and Biotechnology Laboratory (ARBL, 
3107 Rampart Road, Fort Collins, CO 80523) for ongoing research at the facility.  Follicular 
fluid was aspirated from follicles on these ovaries using a syringe fitted with an 18-gauge needle. 
The fluid was separated into Petri dishes and oocytes were visualized under a dissecting 
microscope. Oocytes were transferred to a 15mL conical tube containing 3% bovine serum 
albumin (BSA) in 1% phosphate buffered saline (PBS) using an embryo pipette and stored at 
4°C until needed.  
  Serum from vaccinated mares of known titer levels was obtained from stored samples 
previously collected as part of a study on SpayVac immunocontraception (Roelle, USGS, Pauls 
Valley, OK).  Serum samples from 8 different mares of high titer levels were chosen and used 
throughout the study (Appendix I). Serum of two non-vaccinated mares was obtained from 
samples previously collected and stored as part of ongoing research at the ARBL. All serum 
samples were stored at -80°C until needed. Non-vaccinated mares were of known reproductive 




Sample preparation and protein isolation 
 Isolation of total protein from oocytes was performed using radioimmunoprecipitation 
assay (RIPA) lysis buffer (Appendix II). Whole bovine oocytes were removed from storage and 
washed in PBS. Cumulus cells were mechanically stripped from the oocytes by a series of 
passages through an embryo pipette while the oocytes were suspended in PBS. The oocytes were 
then placed in a 1.7mL conical tube containing RIPA lysis buffer. The samples were 
homogenized twice using a homogenizing pestle and centrifuged for 10 minutes at 10,000 
revolutions per minute at 4°C. The supernatant containing the protein was transferred to a 
separate 1.7mL conical tube and the pellet was discarded.  Protein was isolated just prior to use 
and never frozen. 
 To isolate protein from the zona pellucida and ooplasm fractions of oocytes, the zona 
pellucidae were first stripped from the oocytes by removing them from storage, washing in PBS 
and placing them in a Petri dish containing a droplet of 100μL PBS. Ultra-sharp splitting blades 
(Bioniche, Pullman, WA, catalog #ESE020) were used to make an incision in the zona pellucida, 
allowing the ooplasm to be released and separated from the zona pellucida.  The zona pellucida 
was then washed once more in PBS to free it of extra cells and placed in a 1.7mL tube. Likewise, 
once the oocytes are lysed, the ooplasm was recovered using an embryo pipette and transferred 
to a 1.7mL conical tube. Protein was then isolated from zona pellucidae and ooplasm as 
described above for whole oocytes.  
 
BLAST analysis 
 The protein sequences of ZP3 and ZP4 were compared among species using the National 
Library of Medicine BLAST. The protein sequence for each zona protein (Appendix V) was 
28 
 
entered into the tool and queried against all of the public sequence databases (Appendix V). 
Percent identity for each sequence to other protein sequences in the database is reported. Percent 
identity represents the extent to which the two protein sequences have the same residues at the 
same positions in an alignment. The higher the percentage, the more similar the protein 
sequences are. The percent identity between bovine, porcine, and equine ZP3 and ZP4 are 
reported (Table 1).  
 
Western blot analysis 
The presence of ZP3 and ZP4 in bovine oocytes was determined by Western blot 
analysis. Protein samples were incubated with 6x sample buffer containing dithiothreitol (DTT; 
Appendix IV) for 5 minutes at 95°C prior to loading into 12% 1.5mm SDS-page polyacrylamide 
gels (Appendix III). Electrophoresis was conducted at 30mA for 1 hour at room temperature and 
protein was transferred at 100V for 1 hour at 4°C to a Protran nitrocellulose membrane (GE 
Healthcare Life Sciences, Pittsburgh, PA, Catalog #10402468).  Membranes were blocked in 5% 
blocking buffer (5g non-fat dried milk in 100mL 1X TBST) for 1 hour at room temperature and 
washed with 1X TBST (three 5 minute washes). Membranes were then incubated in either rabbit 
anti ZP4 polyclonal antibody or rabbit anti ZP3 polyclonal antibody (Abgent, San Diego, CA, 
ap12724b and ap17235b respectively) as the primary antibody overnight at 4°C. Primary 
antibodies were diluted 1:100 in 1% blocking buffer (1g non-fat dried milk in 100mL 1X TBST). 
The following day, membranes were washed in 1X TBST and incubated with HRP conjugated 
goat anti rabbit IgG polyclonal secondary antibody (1:1000 in 1% blocking buffer; BioRad, 
Hercules, CA, #170-6515) for 1 hour at room temperature. Membranes were again washed in 1X 
TBST, exposed to Super Signal® West Dura Extended Duration Substrate (Thermo Scientific, 
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Rockford, IL, #34075) and imaged immediately on a Molecular Imager ChemiDoc XRS+ 
System (Bio-Rad, Hercules, CA). The absence of non-specific binding was confirmed by adding 
100μg of ZP3 or ZP4 synthetic blocking peptide (Abgent, San Diego, CA, bp1723b and 
bp12724b respectively) to each primary antibody dilution prior to incubation. The westerns blots 
were then carried out as described above.   
 The immunoreactivity of anti pZP antibodies in the serum of SpayVac vaccinated mares 
to oocyte and zona protein was determined by modifying the Western blot protocol detailed 
above.  Protein isolated from whole oocytes or zona pellucidae were loaded into a 
polyacrylamide gel in duplicate, separated by electrophoresis, transferred to a nitrocellulose 
membrane, and blocked for 1 hour at room temperature in 5% blocking buffer. Membranes were 
washed with 1X TBST and cut down the middle, such that each half contained one set of the 
duplicate protein samples, and kept separate for the remainder of the protocol. One half of each 
membrane was incubated in a 1:50 dilution of serum from a SpayVac vaccinated mare in 1% 
blocking buffer, while the other half was incubated in a 1:50 dilution of serum from a non-
vaccinated mare in 1% blocking buffer as a negative control. Membranes were incubated in these 
serum dilutions overnight at 4°C.  The following day, the membranes were washed in 1X TBST 
and incubated with HRP conjugated goat polyclonal secondary antibody to horse IgG (1:10,000 
in 1% blocking buffer; Abcam, San Francisco, CA, ab102396) for 1 hour at room temperature. 
Membranes were again washed in 1X TBST, exposed to Super Signal® West Dura Extended 
Duration Substrate, and imaged immediately on a Molecular Imager ChemiDoc XRS+ System.  
As a loading control, after the above procedure was completed, the membrane that was 
incubated with non-vaccinated serum was reanalyzed using rabbit anti ZP3 polyclonal antibody. 
Specifically, after imaging, the membrane was re-blocked in 5% blocking buffer for 1 hour at 
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room temperature and incubated with rabbit anti ZP3 polyclonal antibody overnight at 4°C. The 
following day, the membrane was incubated with HRP conjugated goat anti rabbit IgG 
polyclonal antibody, exposed to the signal substrate, and imaged once more.  
   
Oocyte immunohistochemistry  
 Three oocytes, each in 10μL sterile PBS, were placed on slides individually and allowed 
to dry at room temperature. Once dry, the oocytes were fixed in 4% paraformaldehyde (PFA) for 
30 minutes. PFA was rinsed off with 1X PBS and the oocytes were then blocked in 5% normal 
goat serum (NGS) in 1% BSA (.1g bovine serum albumin in 10mL 1X PBS) for 2 hours at room 
temperature in a moist chamber.  After washing the blocking solution off with 1X PBS, each 
oocyte was then incubated overnight in a moist chamber at 4°C with one of the following 
solutions: a dilution of serum from a SpayVac vaccinated mare, a dilution of serum from a non-
vaccinated mare, or 1% BSA as a negative control. The serum dilutions were all 1:50 in 1% 
BSA. The following day, the oocytes were washed in 1X PBS and incubated with HRP 
conjugated goat anti horse IgG polyclonal secondary antibody (1:1000 in 1% BSA) for 1 hour at 
room temperature in a moist chamber. The secondary antibody was washed off with 1X PBS. 
Immpact DAB Peroxidase Substrate Solution (Vector Laboratories, Burlingame, CA, Catalog 
#SK-4105) was applied to each oocyte for 10 minutes, rinsed off with water to stop the reaction, 
and allowed to dry. Once dry, slides were mounted with coverslips using cytoseal (Thermo 





BLAST analysis of ZP3 and ZP4 protein sequences 
 The protein sequences for bovine ZP3 and ZP4 were compared to those of the horse 
using BLAST analysis. BLAST finds regions of local similarity between protein sequences and 
reports the percent identity between matches (Table 1). According to these results, bovine and 
equine ZP3 and ZP4 are ≥ to 75% homologous for all sequences. Likewise, comparing equine 
and bovine sequences to those of the pig resulted in at least 75% homology among the species 
(Table 1).  
 
Table 1: BLAST analysis of ZP3 and ZP4 protein sequences 
 
 
Presence of ZP3 and ZP4 in bovine oocyte and zona protein 
 Western blot analysis confirmed the expression of ZP3 and ZP4 proteins in protein 
isolated from whole bovine oocytes (Figure 1). Bovine ZP3 has a predicted weight of 46kDa and 
bovine ZP4 is predicted at 59kDa. The Western blots for these respective proteins show protein 
bands at the correct molecular weights according to a molecular weight standard loaded into the 
left-most lanes of each gel (Figure 1). Western blots were repeated twice for each antibody with 




Figure 1: Western blot analysis of bovine oocytes for ZP3 and ZP4 
 
Western blot analysis of protein isolated from whole bovine oocytes (7.5 oocytes per 
lane) using (a) rabbit anti ZP3 polyclonal antibody or (b) rabbit anti ZP4 polyclonal 
antibody. Molecular weight standards appear in the left-most lanes of each gel.  
  
Protein isolated from whole bovine oocytes, bovine oocyte ooplasm, and bovine zona 
pellucidae was assessed individually to determine whether all three fractions express ZP3.  
Protein was loaded into a polyacrylamide gel in both 1 and 5 oocyte-per-lane quantities. Western 
blot analysis revealed the presence of ZP3 in all three fractions and verified that protein isolated 
from 1 zona pellucida is sufficient to run the assay (Figure 2). 
 
 
Figure 2: Western blot analysis for ZP3 of protein isolated from whole bovine oocytes, 
bovine oocyte ooplasm and bovine zona pellucidae  
 
Western blot analysis of protein isolated from whole bovine oocytes (lanes 1 and 4), 
bovine oocyte ooplasm (lanes 2 and 5), and bovine zona pellucida (lanes 3 and 6) using 
rabbit anti ZP3 polyclonal antibody. Lanes 1-3 contain protein isolated from 1 oocyte per 
lane. Lanes 4-6 contain protein isolated from 5 oocytes per lane.  Molecular weight 




Immunoreactivity of serum from SpayVac vaccinated mares to bovine oocyte protein 
 A modified Western blot approach was used to assess the immunoreactivity of serum 
from SpayVac vaccinated mares to bovine oocyte protein. Antibodies in the serum from a 
SpayVac vaccinated mare bound bovine oocyte protein (Figure 3b). Antibodies in the serum 
from a non-vaccinated mare did not bind the protein (Figure 3a), confirming that the 
immunoreactivity of serum from a vaccinated mare to oocyte protein is a result of antibodies 
produced in response to SpayVac vaccination. The protein bands appeared at the correct 
molecular weight range for ZP3. This experiment was repeated four times to verify consistency. 
Each time the experiment was repeated, serum from different mares and newly isolated protein 
samples were used. 
 
 
Figure 3: Western blot analysis of protein isolated from whole bovine oocytes using serum 
from a SpayVac vaccinated mare 
 
Western blot analysis of protein isolated from whole bovine oocytes (2 per lane) using (a) 
serum from a non-vaccinated mare and rabbit anti ZP3 polyclonal antibody as a loading 
control, or (b) serum from a SpayVac vaccinated mare. Molecular weight standards 
appear in the left-most lanes of each gel.  
 
Localization of anti pZP antibody binding to the zona pellucida of bovine oocytes 
Whole bovine oocytes were mounted on slides to locate the binding of anti pZP 
antibodies. Immunohistochemical staining using serum from a SpayVac vaccinated mare 
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revealed localization of anti pZP antibodies to the zona pellucida of the bovine oocyte (Figure 
4a). Immunohistochemical staining of oocytes using serum from a non-vaccinated mare was 
comparable to that of the negative control (Figures 4b and 4c). IHC experiments were repeated 
three times with different serum samples and oocytes. 
 
 
Figure 4: Localization of anti pZP antibodies to the zona pellucida of the bovine oocyte 
 
Immunhistochemical staining of whole bovine oocytes using (a) serum from a SpayVac 
vaccinated mare diluted 1:50 in 1% BSA, (b) serum from a non-vaccinated mare diluted 
1:50 in 1% BSA, or (c) 1% BSA as a negative control. (bars = 20μm) 
 
Discussion of Results 
 These experiments were performed to develop an assay to investigate the 
immunoreactivity of serum from a SpayVac vaccinated mare to zona protein. Bovine and equine 
ZP3 and ZP4 are ≥ 75% homologous for all sequences according to BLAST analysis (Table 1). 
Likewise, comparing equine and bovine ZP3 and ZP4 sequences to those of the pig resulted in at 
least 75% homology among species (Table 1). Western blot analysis further confirmed the 
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presence of ZP3 and ZP4 in bovine oocytes (Figures 1 and 2). Importantly, these experiments 
determined that the protein content in the zona pellucida from one oocyte is sufficient to run the 
assay.  
While all four zona proteins are of interest, some studies argue whether the pig has ZP1 
and recombinant antibodies to ZP2 are not commercially available. ZP3 was chosen for use in 
this experiment due to its critical role in sperm binding and fertilization, along with its assumed 
participation in the mechanism of action of SpayVac. ZP4 was also of interest due to its role as a 
structural protein. Western blot and BLAST results therefore confirm the adequacy of using 
bovine oocytes to develop the Western blot approach. 
  We then investigated the immunoreactivity of antibodies in serum from SpayVac 
vaccinated mares to zona protein using a modified Western blot approach. Western blot analysis 
of bovine oocyte protein using serum dilutions from SpayVac vaccinated and non-vaccinated 
mares revealed that antibodies in the serum from SpayVac vaccinated mares are immunoreactive 
to bovine oocyte protein samples (Figure 3). Serum from non-vaccinated mares did not have 
antibodies immunoreactive to the protein. This confirms that the antibodies capable of binding 
zona protein present in the serum of vaccinated mares are not endogenously present in the serum 
of non-vaccinated mares. These antibodies are likely horse polyclonal antibodies to porcine zona 
pellucida, or horse anti pZP antibodies. As the name implies, these antibodies are raised in the 
horse in response to vaccination with porcine zona protein. Likewise, these anti pZP antibodies 
in the serum of SpayVac vaccinated mares recognized protein at the correct molecular weight 
range for ZP3, suggesting that antibodies in the serum of vaccinated mares are capable of 
binding the zona pellucida of mature bovine oocytes, perhaps primarily at ZP3 binding sites.   
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Immunohistochemistry (IHC) techniques were also adapted to use serum as the primary 
antibody. This modification demonstrates that anti pZP antibodies in the serum of SpayVac 
vaccinated mares bind to the zona pellucida of mature bovine oocytes (Figure 6). While high 
background staining was observed from immunohistochemical labeling of bovine oocytes using 
serum from a non-vaccinated mare, the background staining was comparable to that of the 
negative control.  
These experiments led to the development of a repeatable assay that can be used to 
investigate the immunoreactivity of serum to a protein of interest. In the process, Western blot 
and immunohistochemical analysis also confirmed the presence and specificity of antibodies in 
the serum of SpayVac vaccinated mares for bovine oocyte protein. Since antibodies in the serum 
of non-vaccinated mares fail to recognize and bind the protein samples, anti pZP antibodies 
raised in the vaccinated horse against the SpayVac vaccine are most likely responsible for the 













CHAPTER IV: IMMUNOREACTIVITY OF ANTI PZP ANTIBODIES FROM THE SERUM 





 We investigated the immunoreactivity of serum from SpayVac vaccinated mares to 
equine zona protein using a modified Western blot approach. Western blot analysis for anti-
porcine zona pellucida (anti pZP) antibodies from SpayVac vaccinated mares was first conducted 
using protein isolated from whole equine oocytes and equine zona pellucidae, as the zona 
pellucida is of primary interest in investigating the mechanism of action of the vaccine. Previous 
studies have reported follicular dysgenesis following vaccination with the pZP antigen (Skinner 
et al. 1984, Kirkpatrick et al. 1995), suggesting a mechanism of action beyond the scope of 
simply binding to the zona pellucida of ovulated oocytes. We therefore conducted Western blot 
analysis of equine ovarian and follicular tissues as well. Immunohistochemical analysis of 
consecutive slices of equine ovarian and follicular tissues, along with whole equine oocytes, was 
used to determine the site of binding of anti pZP antibodies to these tissues. To verify the 
specificity of anti pZP antibodies for zona protein, ZP3 and ZP4 blocking peptides were used to 
pre-saturate the serum from a SpayVac vaccinated mare prior to the serum being used as the 
primary antibody for immunohistochemical analysis. Likewise, Western blot membranes were 
pre-incubated with polyclonal antibodies to ZP3 and ZP4 before incubation with serum from a 
SpayVac mare. Finally, serum samples from mares with known low- and high- titer levels were 
analyzed side by side in a Western blot analysis to test their relative immunoreactivity to the 
same equine zona protein samples. Results indicate immunoreactivity of anti pZP antibodies 
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from the serum of SpayVac vaccinated mares, with both high- and low- antibody titers, to 
isolated equine zona protein.  
Materials and Methods 
Samples 
We obtained equine ovaries, renal tissue, and oocytes from necropsy samples previously 
collected and stored at the Animal Reproduction Biotechnology Laboratory (ARBL, 3107 
Rampart Road, Fort Collins, CO 80523) at Colorado State University as part of ongoing 
research. Follicular fluid was aspirated from large follicles visible on the ovaries and oocytes 
were recovered as described for the bovine model. The remainder of the follicles were lysed and 
washed with phosphate buffered saline (PBS). The washing fluid was then searched using a 
dissecting microscope for additional oocytes released from smaller follicles. Oocytes were stored 
in PBS at 4°C.  Tissue was excised from the ovarian stroma and follicular walls of equine 
ovaries. Tissues were fixed in 4% paraformaldehyde (PFA) overnight. The following day, the 
fixative was replaced with 70% ethanol for storage and samples were sent to the Colorado State 
Veterinary Diagnostics Laboratory (Fort Collins, CO) to be embedded in paraffin blocks. The 
rest of the tissues were frozen and stored at -80°C until thawed for protein isolation. 
Serum from vaccinated mares of known titer levels was obtained from stored samples 
previously collected as part of a study on SpayVac immunocontraception (Roelle, USGS, Pauls 
Valley, OK).  Serum samples from eight mares of high titer levels and one mare of low titer level 
were chosen and used throughout the study (Appendix I). Serum from two non-vaccinated mares 
was obtained from samples previously collected and stored as part of ongoing research at the 
ARBL. All serum samples were stored at -80°C until needed. Non-vaccinated mares were of 




Protein isolation and quantification 
Protein was isolated from equine oocytes and zona pellucidae using 
radioimmunoprecipitation assay (RIPA) lysis buffer (Appendix II) as described for the bovine 
model. Protein from ovarian, follicular, and renal tissue was also isolated utilizing RIPA lysis 
buffer. Tissue samples were homogenized in RIPA lysis buffer, sonicated on ice to disrupt 
cellular membranes, and centrifuged at 10,000 revolutions per minute at 4°C for 10 minutes. The 
resulting supernatant containing the protein was separated into a 1.7mL conical tube and used 
immediately. Protein content was quantified following the manufacturer’s protocol for the Pierce 
BCA Protein Assay Kit (Thermo Scientific, catalog #23227). Standards containing 2.0mg/mL 
bovine serum albumin and working reagents were prepared. A microplate was loaded with 
12.5μL of each standard or unknown sample and 100μL of working reagent per well. The 
microplate was then incubated for 30 minutes at 37°C. Protein content was quantified using 
spectrophotometry with the Synergy 2 Multi-Mode Microplate Reader (Biotek, Winooski, VT). 
Unknown sample concentrations were determined by comparison to the standard curve of the 
known standards. 
 
Western blot analysis 
 The immunoreactivity of anti pZP antibodies in the serum of SpayVac vaccinated mares 
to protein isolated from whole equine oocytes, equine zona pellucidae, ovarian tissue, and 
follicular tissue was determined using the Western blot techniques developed in the bovine 
model.  Protein was isolated from these tissues and incubated with 6x sample buffer (Appendix 
IV) containing dithiothreitol (DTT) for 5 minutes at 95°C prior to loading into 12.0% 1.5mm 
40 
 
SDS-page polyacrylamide gels in duplicate (Appendix III). Electrophoresis was conducted for 1 
hour at 30mA and protein was transferred to a Protran nitrocellulose membrane (GE Healthcare 
Life Sciences, Pittsburgh, PA, Catalog #10402468) for 1 hour at 100V at 4°C.  Membranes were 
blocked in 5% blocking buffer (5g dried milk in 100mL 1X TBST) for 1 hour at room 
temperature and washed with 1X TBST (three, five minute washes). Membranes were then cut 
down the middle, such that each half contained one set of the duplicate protein samples, and kept 
separate for the remainder of the protocol. One half of each membrane was incubated in a 1:50 
dilution of serum from a SpayVac vaccinated mare in 1% blocking buffer (1g dried milk in 
100mL 1X TBST), while the other half was incubated in a 1:50 dilution of serum from a non-
vaccinated mare in 1% blocking buffer. Membranes were incubated overnight at 4°C.  The 
following day, the membranes were washed in 1X TBST and incubated with horseradish 
peroxidase (HRP) conjugated goat polyclonal secondary antibody to horse IgG (1:10,000 in 1% 
blocking buffer; Abcam, San Francisco, CA, ab102396) for 1 hour at room temperature. 
Membranes were washed in 1X TBST, exposed to Super Signal® West Dura Extended Duration 
Substrate (Thermo Scientific, Rockford, IL, #34075) and imaged immediately on a Molecular 
Imager ChemiDoc XRS+ System (Bio-Rad, Hercules, CA).  
Mouse anti beta actin monoclonal antibody (1:100 in 1% BSA; Abcam, San Francisco, 
CA, ab8226) was used for protein isolated from follicular and ovarian tissues, and rabbit anti 
ZP3 polyclonal antibody (1:100 in 1% blocking buffer; Abgent, San Diego, CA, ap17235) was 
used for protein isolated from oocytes and zona pellucidae, as loading controls. After initial 
imaging, the membranes were blocked in 5% BSA (.5g bovine serum albumin in 10mL 1X 
TBST) or 5% blocking buffer, respectively, for 1 hour at room temperature. Membranes were 
then incubated with their respective antibodies overnight at 4°C. The following day, the 
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membranes were washed in 1X TBST and incubated with either HRP conjugated donkey anti 
mouse IgG polyclonal antibody (1:1000 in 1% BSA; Abcam, San Francisco, CA, ab 97030) or 
HRP conjugated goat anti rabbit IgG polyclonal antibody (1:1000 in 1% blocking buffer; 
BioRad, Hercules, CA, 170-6515), depending on the primary antibody used, for one hour at 
room temperature. The membranes were finally exposed to substrate and imaged.  
 Binding specificity was determined by pre-incubation of the Western blot membranes 
with either rabbit anti ZP3 polyclonal antibody or rabbit anti ZP4 polyclonal antibody (Abgent, 
San Deigo, CA, ap17235b and ap12724b respectively). After protein loading, separation, transfer 
to membrane, and blocking, membranes were cut in half. One half of each membrane was pre-
incubated in rabbit anti ZP3 polyclonal antibody (1:100 in 1% blocking buffer) while the other 
half was pre-incubated in rabbit anti ZP4 polyclonal antibody (1:100 in 1% blocking buffer) 
overnight at 4°C. The following day, the membranes were washed in 1X TBST and incubated 
with serum from a SpayVac vaccinated mare (1:50 in 1% blocking buffer) overnight at 4°C. On 
the third day, the membranes were washed in 1X TBST, incubated with HRP conjugated goat 
anti horse IgG polyclonal secondary antibody (1:10,000 in 1% blocking buffer), exposed to 
Super Signal West Dura Extended Duration Substrate, and imaged. As a loading control, after 
imaging the membranes were blocked in 5% BSA and incubated with mouse monoclonal 
antibody to beta actin (1:1000 in 1% BSA in 1X TBST) overnight at 4°C. On the fourth day, the 
membranes were washed in 1X TBST and incubated in HRP conjugated donkey anti mouse IgG 
polyclonal antibody for 1 hour at room temperature. The membranes were then exposed to 
developing substrate and imaged one more time.  
 Relative immunoreactivity of high- and low- titer serum samples was investigated using 
the same Western blot procedures detailed above. The difference being that one half of each 
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membrane was incubated in the serum from a SpayVac vaccinated mare with high antibody titer, 
while the other half was incubated in a dilution of serum from a SpayVac vaccinated mare with 
low antibody titer overnight at 4°C as the primary antibody (Appendix I).  All serum dilutions 
were 1:50 in 1% blocking buffer. HRP conjugated goat anti horse IgG polyclonal antibody 
(1:10,000 in 1% blocking buffer) was used as the secondary antibody. Anti ZP3 and anti beta 
actin polyclonal antibodies were used as loading controls for protein isolated from oocytes and 
tissues, respectively. 
 
Western blot quantification 
 Densitometry was performed using a Molecular Imager ChemiDoc XRS+ System with 
ImageLabTM software (Bio Rad, Hercules CA). Bands were detected by the software and values 
of integrated optical density were exported to an Excel spreadsheet. Each protein band of interest 
was normalized to total protein content in the lane using its respective loading control. Graphs 
were then produced by Excel to compare the normalized densities of protein bands between 
high- and low- titer serum samples. The y-axis of each graph is read as a ratio of protein of 
interest to the loading control. 
 
Immunohistochemistry and Hematoxylin and Eosin (H&E) staining of tissues 
 Four consecutive 5μm sections of tissue were placed on two glass slides, such that each 
slide had two slices of tissue, and incubated overnight at 37°C. The following day, the slides 
were incubated at 55°C for 30 minutes. Citrisolve (Thermo Scientific, Catalog# 22-143975) 
along with an alcohol gradient was then used to dewax and rehydrate the tissue slices. 
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Following rehydration, one of the two slides was subjected to a H&E staining protocol. 
The slide was incubated in hematoxylin for 1 minute, rinsed under running tap water for 5 
minutes, incubated in eosin for 5 minutes, rinsed once more under running tap water, and finally 
dehydrated through an alcohol and citrisolve gradient. The slide was then left to air dry at room 
temperature prior to being mounted with a coverslip using cytoseal and imaged with light 
microscopy. 
Meanwhile, the other slide was boiled in 10mM sodium citrate (pH 6.0) for 20 minutes 
for antigen retrieval. Afterward, the slide was washed in 1X PBS for 10 minutes and blocked in 
5% natural goat serum (NGS) in 1% BSA (0.1g bovine serum albumin in 10mL 1X PBS) at 
room temperature for 2 hours in a wet chamber. After blocking, the slide was drained and blotted 
dry. A dilution of serum from a SpayVac vaccinated mare was applied to the first tissue slice 
while a dilution of serum from a non-vaccinated mare was applied to the second tissue slice on 
the slide. The slide was then incubated overnight in a wet chamber at 4°C. Serum dilutions were 
all 1:50 in 1% BSA. The following day, the slide was washed in 1X PBS and incubated at room 
temperature in a wet chamber for 1 hour with HRP conjugated goat polyclonal secondary 
antibody to horse IgG (1:1000 in 1% BSA, Abcam, ab102396). The slide was washed again in 
1X PBS and Immpact DAB Peroxidase Substrate Solution (Vector Laboratories, Burlingame, 
CA, Catalog #SK-4108) was applied for 10 minutes. To stop the reaction, the slide was rinsed in 
running water for 5 minutes, taken back through the alcohol gradient for dehydration, and 
allowed to dry. The slide was finally mounted with cytoseal (Thermo Scientific, Rockford, IL, 
Catalog #8310-4) and imaged with light microscopy. 
 Binding specificity of anti pZP antibodies to zona protein was determined by pre-
saturating a sample of serum from a SpayVac vaccinated mare with ZP3 and ZP4 synthetic 
44 
 
blocking peptides (Abgent, San Diego, CA, bp1723b and bp12724b respectively) prior to use as 
the primary antibody for immunohistochemical analysis. 30μg of each blocking peptide were 
added to a dilution of serum from a SpayVac vaccinated mare (10μL serum in 500μL 1% BSA). 
The immunohistochemistry protocol was then followed out as described above. HRP conjugated 




 Immunohistochemical staining of the equine oocyte was performed as described for the 
bovine oocytes. A whole equine oocyte was mounted on a slide, fixed in 4% paraformaldehyde, 
and blocked in 7.5% NGS in 1% BSA. The oocyte was then incubated in a 1:50 dilution of 
serum from a vaccinated mare in 1% BSA overnight at 4°C in a wet chamber. The following 
day, the oocyte was incubated in HRP conjugated goat anti horse IgG polyclonal 
antibody(1:1000 in 1% BSA), developed using Immpact DAB Peroxidase Substrate, mounted 
with a coverslip, and imaged using light microscopy. 
 
Results 
Immunoreactivity of serum from SpayVac vaccinated mares to equine zona protein 
 Modified Western blot techniques were used to assess the immunoreactivity of serum 
from SpayVac vaccinated mares to protein isolated from whole equine oocytes and equine zona 
pellucidae. The binding of antibodies in the serum from a SpayVac vaccinated mare to equine 
zona protein was demonstrated (Figure 5b). Serum from a non-vaccinated mare did not have 
antibodies capable of binding the protein, confirming that the immunoreactivity of serum from a 
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vaccinated mare is a result of antibodies produced in response to SpayVac vaccination (Figure 
5). This experiment was repeated twice with different serum and protein samples.  
 
Figure 5: Western blot analysis of protein isolated from equine oocytes and zona pellucidae 
using serum from a SpayVac vaccinated mare 
 
Western blot analysis of protein isolated from equine zona pellucidae (2 per lane; lanes 1 
and 4) and whole equine oocytes (2 per lane; lanes 2 and 3) using (a) serum from a non-
vaccinated mare and anti ZP3 polyclonal antibody as a loading control, or (b) serum from 
a SpayVac vaccinated mare. Molecular weight standards appear in the left-most lanes of 
each gel.  
 
Immunoreactivity of serum from SpayVac vaccinated mares to equine ovarian and follicular 
tissues 
 Western blot analysis revealed the immunoreactivity of serum from a SpayVac 
vaccinated mare to protein isolated from equine ovarian and follicular tissues. Anti pZP 
antibodies in the serum of a SpayVac vaccinated mare bound the protein samples (Figure 6b) 
while antibodies in the serum from a non-vaccinated mare did not bind the protein (Figure 6a). 
Renal tissue was used as a negative control in these experiments. Western blot analysis of equine 





Figure 6: Western blot analysis of protein isolated from equine ovarian and follicular 
tissues using serum from a SpayVac vaccinated mare 
 
Western blot analysis of protein isolated from equine ovarian tissue (lanes 1 and 4), 
equine follicular tissue (lanes 2 and 5), and equine renal tissue (lanes 3 and 6) using (a) 
serum from a non-vaccinated mare and (b) serum from a SpayVac vaccinated mare. 40μg 
of each protein were loaded per lane. Molecular weight standards appear in the left-most 
lane of each gel. Western blot analysis for beta actin of each membrane was performed as 
a loading control.  
 
Localization of anti pZP antibodies from the serum of SpayVac vaccinated mares to the zona 
pellucida of mature and immature equine oocytes 
 Immunohistochemical staining of equine ovarian tissue using serum from a SpayVac 
vaccinated mare located the binding of anti pZP antibodies to the zona pellucidae of immature 
oocytes of primary follicles embedded in the tissue (Figure 7e). Immunohistochemical analysis 
did not locate the binding of anti pZP antibodies to oocytes of primordial follicles, where a zona 
pellucida is not yet formed (Figure 7b). Antibodies in the serum from a non-vaccinated mare did 
not bind the oocytes; implying antibodies present in the serum of vaccinated mares are a result of 
SpayVac vaccination (Figures 7c and 7f).  H&E staining enhances visualization of structures 
(Figures 7a and 7d). Similarly, immunohistochemical staining of a whole equine oocyte using 
serum from a SpayVac vaccinated mare located the binding of anti pZP antibodies to the zona 




Figure 7: Anti pZP antibody binding to the zona pellucida of oocytes in primary follicles 
embedded in ovarian tissue 
 
Immunohistochemical staining of equine ovarian tissue using (b and e) serum from a 
SpayVac vaccinated mare and (c and f) serum from a non-vaccinated mare. Anti pZP 
antibodies bind the zona pellucida of oocytes in primary follicles (e) but did not bind 
primordial follicles where the zona pellucida has yet to be formed (b). 
Immunohistochemical staining using serum from non-vaccinated mares (c and f) is not 












Figure 8: Anti pZP antibody binding to the zona pellucida of the equine oocyte 
 
Immunohistochemical staining using serum from a SpayVac vaccinated mare reveals 
localization of anti pZP antibodies to the zona pellucida of the mature, pre-ovulatory 
equine oocyte. (bar = 20μm) 
 
Specificity of anti pZP antibodies in the serum of SpayVac vaccinated mares for equine zona 
protein 
 Pre-incubation of the Western blot membrane with rabbit anti ZP3 polyclonal antibody 
prior to incubation with serum from a SpayVac vaccinated mare completely blocked the ability 
of anti pZP antibodies to bind to the protein sample. Anti pZP antibodies maintained their ability 
to bind the protein sample following pre-incubation with rabbit anti ZP4 polyclonal antibody. 
This indicates that anti pZP antibodies in the serum of a SpayVac vaccinated mare may be more 






Figure 9: Western blot analysis of equine ovarian and follicular tissues using serum from a 
SpayVac vaccinated mare following pre-incubation with anti ZP3 and anti ZP4 polyclonal 
antibodies 
 
Western blot analysis of protein isolated from equine ovarian (lanes 1 and 4), equine 
follicular (lanes 2 and 5), and equine renal (lanes 3 and 6) tissues using serum from a 
SpayVac vaccinated mare following pre-incubation with (a) rabbit anti ZP3 polyclonal 
antibody and (b) rabbit anti ZP4 polyclonal antibody. Western blot analysis using anti-
beta actin antibody was performed as a loading control. Renal tissue was used as a 
negative control. Molecular weight standards appear in the left-most lanes of each gel. 
40μg of protein were loaded per lane.  
 
 Similarly, immunohistochemical techniques were modified to further investigate the 
specificity of anti pZP antibodies to zona protein. Pre-incubation of serum from a SpayVac 
vaccinated mare with ZP3 and ZP4 blocking peptides prior to immunohistochemical staining of 
equine ovarian tissue using the serum inhibited the binding of anti pZP antibodies to the oocyte 
(Figure 10b). When the serum from the same SpayVac vaccinated mare was used in the absence 
of blocking peptides for immunohistochemical analysis, anti pZP antibodies in the serum 
localized to the zona pellucida of an oocyte embedded in the tissue (Figure 10c). H&E staining 
of a consecutive tissue slice enhances visualization of the cellular structures. Collectively, these 







Figure 10: Immunohistochemical analysis of equine ovarian tissue using serum from a 
SpayVac vaccinated mare following pre-saturation with ZP3 and ZP4 blocking peptides 
 
Immunohistochemical staining of equine ovarian tissue using (b) serum from a SpayVac 
vaccinated mare demonstrates localization of anti pZP antibodies to the zona pellucida of 
an oocyte in a primary follicle embedded in the tissue. Pre-saturation of serum from the 
same mare with ZP3 and ZP4 blocking peptides prior to immunohistochemical staining 
of equine ovarian tissue blocked the ability of anti pZP antibodies to bind the oocyte (c). 
(bar = 20μm) 
 
Relative immunoreactivity of anti pZP antibodies from the serum of SpayVac vaccinated mares 
with high and low antibody titers to equine zona protein 
 Western blot analysis was used to compare the immunoreactivity of anti pZP antibodies 
in the serum of SpayVac vaccinated mares with high and low antibody titer levels to equine zona 
protein. The first serum sample had a titer level of 178.33 while the latter was 39.66, 
representing a 4x difference in titer levels between the samples. The binding of anti pZP 
antibodies from the serum a SpayVac vaccinated mare with high antibody titers to protein 
isolated from equine oocytes (Figure 11a) and equine ovarian and follicular tissues (Figure 11c) 
was verified by Western blot analysis. Likewise, the binding of anti pZP antibodies from the 
serum of a SpayVac vaccinated mare with low antibody titers to the same protein samples was 
demonstrated (Figures 11b and 11d). Antibodies to ZP3 and beta-actin were used as loading 
controls and as normalization factors in the quantitative analysis of relative protein expression. A 
Molecular Imager ChemiDoc XRS+ System was used to perform densitometry to detect the 
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relative immunoreactivity between high and low titer serum samples. Integrated optical density 
was detected and recorded for each protein band, and then normalized against the respective 
loading control for each lane. Finally, the ratio of protein to loading control was expressed as a 
function of high and low titer serum samples (Figures 11e and 11f). While it appears that anti 
pZP antibodies in the serum of SpayVac vaccinated mares bind the protein samples without 
regard to titer level, this experiment was merely a demonstration of concept and no statistical 
evidence can be offered.  
 
Discussion of Results 
Western blot analysis of equine oocyte and zona protein using serum from a SpayVac 
vaccinated mare revealed immunoreactivity of antibodies in the serum to the protein samples 
(Figure 5).  Antibodies in the serum from a non-vaccinated mare did not bind the protein 
samples. This indicates that the antibodies immunoreactive to the protein samples found in serum 
from SpayVac vaccinated mares are a result of SpayVac vaccination, and are not endogenously 
present in the non-vaccinated mare. These antibodies are likely horse polyclonal antibodies to 
porcine zona pellucida (anti pZP). As the name implies, they are raised in the vaccinated horse 
against porcine zona protein. Western blot analyses confirmed these antibodies to be 
immunoreactive to equine ZP3. Immunohistochemical analysis located the binding of anti pZP 
antibodies to the zona pellucida of a mature, pre-ovulatory oocyte aspirated from a Graafian 
follicle (Figure 8). 
Since previous studies have suggested a mechanism of action beyond anti pZP antibodies 
only binding mature oocytes (Skinner et al. 1984, Kirkpatrick et al. 1995), anti pZP reactivity to 





Figure 11: Immunoreactivity of anti pZP antibodies from the serum of SpayVac vaccinated 
mares with high and low antibody titers 
 
Western blot analysis using (a. and c.) serum from a SpayVac vaccinated mare with high 
antibody titers or (b. and d.) serum from a SpayVac vaccinated mare with low antibody 
titers. Lanes 1 and 2 each contain protein isolated from 2 equine oocytes, lanes 3 and 5 
each contain 40μg of protein isolated from equine follicular tissue, and lanes 4 and 6 each 
contain 40μg of protein isolated from equine ovarian tissue. Anti ZP3 antibody (a. and 
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weight standards appear in the left-most lane of each gel. Densitometry was performed 
using a Molecular Imager ChemiDoc XRS+ System, with values expressed as integrated 
optical density. Immunoreactivity values are normalized to total protein content using 
ZP3 (e.) or beta-actin (f.).  Relative immunoreactivity of anti pZP antibodies from high 
and low titer serum to protein isolated from equine oocytes (e.) and equine ovarian and 
follicular tissues (f.) is illustrated.  
 
 
of anti pZP antibodies to protein isolated from these tissues (Figure 6). Immunohistochemical 
analysis of equine ovarian tissue localized the binding of anti pZP antibodies to the zona 
pellucidae of immature oocytes of primary follicles embedded in the tissue (Figure 7). 
Interestingly, immunohistochemical analysis of the equine follicular wall could not replicate the 
immunoreactivity described in the Western blot analysis to follicular tissue. The synthesis of the 
zona pellucida is thought to be an integrated process where both the oocyte and surrounding 
granulosa cells contribute to the overall creation of the structure (Sinowatz et al. 2001, 
Blackmore et al. 2004).  It is likely that the granulosa cells express zona protein precursors that 
are recognized by anti pZP antibodies during Western blot analysis. While Western blot analysis 
may have detected these zona protein precursors in the granulosa cells of follicular tissue, 
immunohistochemical analysis did not confirm this. When protein is isolated for Western blot 
analysis, tissue is homogenized, sonicated and subjected to a cell lysis buffer. This disrupts 
cellular membranes and releases intracellular proteins, which are used in the analysis. 
Alternatively, preparation of tissue for immunohistochemical analysis does not involve these 
protein isolation methods. Similar to Western blot results, antibodies in the serum from non-
vaccinated mares were unable to bind the tissues.  
Anti pZP antibodies from the serum of SpayVac vaccinated mares were found to be 
specific for zona protein 3. Pre-saturating a serum sample from a SpayVac vaccinated mare with 
ZP3 and ZP4 blocking peptides successfully blocked the ability of anti pZP antibodies to bind 
54 
 
the tissues during immunohistochemical analysis (Figure 10). Similarly, pre-incubating the 
Western blot membrane with anti ZP3 antibodies prior to incubation with serum from a SpayVac 
vaccinated mare inhibited the ability of antibodies in the serum to bind the protein samples 
(Figure 9). Pre-incubation of the Western blot membrane with anti ZP4 antibodies attenuated the 
ability of anti pZP antibodies to bind, but did not remove it completely (Figure 9). These 
experiments are indicative of both a specificity of anti pZP antibodies for equine zona protein 3 
as well as a lack of non-specific binding. The antibodies are, in fact, binding zona protein in 
these tissues and protein samples.  
Following SpayVac vaccination in late March 2011, serum samples were taken from 
treated mares in early May 2011 and analyzed for titer level. Although each mare was vaccinated 
with the same dose of SpayVac, individual differences in immune system response may result in 
variable titer levels and efficacy among mares. Accordingly, 2 of the 9 serum samples used in 
this study were from SpayVac treated mares that were still able to conceive in 2011 despite 
vaccination. Nonetheless, experiments demonstrated that all 9 of the serum samples contained 
antibodies produced in response to SpayVac vaccination that are immunoreactive to equine zona 
protein. To further investigate whether the serum from a mare of high titer level is more 
immunoreactive to zona protein than serum from a mare with a low titer level, who also 
conceived despite vaccination, the Western blot protocol developed above was conducted with 
both serum samples for zona protein side-by-side.  While the high titer serum sample had greater 
than four times the titer level of the low titer serum sample, both serum samples appeared to be 
immunoreactive to the protein sample (Figure 11). Western blot analysis revealed that both 
serum samples were able to bind zona protein, with no clear trend of one sample being more 
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effective than the other. With that said, this is purely a demonstration of concept as sufficient 
sample size to determine statistical power for the observation was not pursued.  
As anticipated, results reveal immunoreactivity of anti pZP antibodies raised in the horse 
in response to SpayVac vaccination to zona protein. The zona pellucida emerges early on in 
folliculogenesis, and is abundantly apparent by the primary follicle stage of development. Anti 
pZP antibodies appear immunoreactive to not only the zona pellucidae of mature, pre-ovulatory 
oocytes, but also immature oocytes embedded in ovarian tissue.  While Western blot analyses 
revealed immunoreactivity between anti pZP antibodies and protein isolated from equine 
follicular tissue, immunohistochemical analysis did not demonstrate this immunoreactivity, 
indicating that this topic should be investigated further. Collectively, results illustrate that anti 
pZP antibodies are capable of binding equine zona protein of both mature, pre-ovulatory oocytes 
and oocytes of immature, developing follicles. It is important to note, however, that while these 
experiments demonstrate an immunoreactivity of anti pZP antibodies to zona protein, it has yet 
to be demonstrated whether anti pZP antibodies are able to permeate the ovary or available in the 
follicular fluid following vaccination and thus able to act at these levels in vivo. These 
experiments merely illustrate a model by which anti pZP antibodies in the serum of SpayVac 












Immunocontraception with the porcine zona pellucida (pZP) antigen can be a highly 
effective means of wild horse contraception. Porcine zona pellucida vaccines have proven to be 
safe and predictable, with minimal side effects following injection and exceptional ease of 
administration. (Ransom et al. 2011, NRC 2013)  Nonetheless, the contraceptive mechanisms of 
pZP vaccines remain unclear. This study thus investigated the fundamental question of whether 
anti pZP antibodies produced in response to SpayVac® vaccination are immunoreactive to equine 
zona protein. When used as a vaccine in another species, pZP stimulates an immune response 
that can be measured by antibody titer levels and results in infertility. Infertility is thought to be 
achieved by the binding of anti pZP antibodies to the zona pellucida proteins on mature oocytes, 
thereby inhibiting sperm binding and penetration (Sacco 1977, Liu et al. 1989, Kirkpatrick et al. 
1990). Other studies have demonstrated follicular dysgenesis following vaccination; including 
diminished ovulatory ability, absence of mature oocytes and follicles, and a decline in ovarian 
estrogen secretion (Skinner et al. 1984, Kirkpatrick et al. 1995). Collectively, these studies 
suggest that anti pZP antibodies act on not only ovulated oocytes in the oviduct, but also on 
ovarian tissue, follicular tissue, and immature oocytes. However, the central question underlying 
these mechanisms that remains unclear is whether anti pZP antibodies are capable of recognizing 
equine zona protein.  
Through Western blot and immunohistochemical analysis, this study demonstrated an 
immunoreactivity of anti pZP antibodies produced in response to SpayVac vaccination to equine 
zona protein when made artificially available to one another in vitro. A bovine model was used 
to develop an assay to test the immunoreactivity of antibodies present in the serum of a 
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vaccinated animal to a protein of interest. Bovine samples were chosen due to the relative ease of 
which they are obtained in large quantities and the strong homology of bovine zona proteins to 
equine. Once the assay was consistent and repeatable, equine samples were used in place of the 
bovine samples. Western blot analysis revealed immunoreactivity of anti pZP antibodies 
produced in response to SpayVac vaccination to protein isolated from equine oocytes, equine 
zona pellucidae, equine follicular tissue, and equine ovarian tissue (Figures 5 and 6). 
Immunohistochemical analysis then verified the location of binding of anti pZP antibodies to the 
zona pellucidae of both immature oocytes embedded in ovarian tissue and mature, pre-ovulatory 
oocytes isolated from Graafian follicles (Figures 7 and 8). These results lend insight into not only 
the mechanism underlying the interference of the sperm-egg interaction detailed by Kirkpatrick 
et al. (1995), but also the follicular dysgenesis reported in other studies.  
The immunoreactivity of anti pZP antibodies to protein isolated from equine ovarian 
tissues is explained by the localization of antibodies to the zona pellucidae of immature oocytes 
embedded in the tissue. Likewise, the immunoreactivity to equine follicular tissue demonstrated 
by Western blot analysis is thought to be due to the presence of zona protein precursors in the 
granulosa cells of the follicle. However, multiple attempts to analyze follicular tissue by 
immunohistochemistry failed to demonstrate localization to these cells. The synthesis of the zona 
pellucida is thought to be an integrated process where both the oocyte and surrounding granulosa 
cells contribute to the overall creation of the structure (Sinowatz et al. 2001, Blackmore et al. 
2004). It is therefore likely that both the granulosa cells and oocyte express, at least in small 
quantities, zona protein precursors. While Western blot analysis may have detected these zona 
protein precursors due to its high level of sensitivity (in the femtogram level) and stringent cell 
lysis protocol to release intracellular proteins, high background staining observed in 
58 
 
immunohistochemical analysis may have masked any localization to these cells. Ramos-Vara et 
al. (2008) indicates that high background staining is known to occur when the primary antibody 
used is from the same species as the tissue being analyzed. This is the case with figures 7, 8, and 
10 where both the tissue and antibody used are of equine origin. Likewise, when protein is 
isolated for Western blot analysis, tissue is homogenized, sonicated and subjected to a cell lysis 
buffer. This disrupts cellular membranes and releases intracellular proteins, which are used in the 
analysis. Alternatively, preparation of tissue for immunohistochemical analysis does not involve 
these protein isolation methods. Since zona protein precursors in the granulosa cells are not 
integral membrane proteins, and therefore not expressed on the cell surface, it is likely that 
immunohistochemical analysis cannot detect these proteins as they were not exposed. 
 Although results indicate an immunoreactivity of anti pZP antibodies raised in the mare 
in response to SpayVac vaccination to equine zona protein, there are many limitations to this 
study.  First, while there are three pZP vaccines currently being reported for use in horses, 
Zonastat-H®, PZP-22, and SpayVac, this study focused on SpayVac as it is less documented in 
published literature and emerged as a longer-lasting alternative to the other two vaccines. 
Although all three vaccines incorporate the same pZP antigen, they are not a homogenous set of 
compounds. Rather, differences in antigen preparation result in variations in purity and protein 
content among the vaccines (NRC 2013). Miller et al. (2009) suggests that these differences in 
antigen preparation may account for the variability in efficacy levels observed among vaccines. 
In addition to focusing on only one vaccine, serum samples from vaccinated mares were 
selectively chosen for their high antibody titer levels, with the exception of figure 11. 
Differences in antibody titer and quality depend on the animal immunized and contribute to 
variability in efficacy among individuals (Ramos-Vara 2005, NRC 2013). Therefore, not only 
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are the results of this study specific for anti pZP antibodies produced in response to SpayVac, but 
they may also not be indicative of antibodies produced in animals of all titer levels. Despite the 
attempt to compare high- and low- titer serum samples in figure 11, this experiment was simply 
illustrative of proof of concept and statistical evidence cannot be offered.  
Similarly, the use of serum from a SpayVac vaccinated mare as a primary antibody in 
Western blot and immunohistochemical analysis is analogous to the use of a polyclonal antibody. 
As detailed by Ramos-Vara (2005), polyclonal antibodies are produced by immunizing an 
animal with purified antigen. The animal’s immune response produces antibodies against the 
antigen. These antibodies migrate into the blood where serum containing the antibodies can be 
harvested and used as antisera against the antigen during immunological protocols (Ramos-Vara 
2005). In the case of SpayVac vaccination, a horse is immunized with purified pZP antigen, 
resulting in the production of anti pZP antibodies. Serum harvested from the vaccinated horse 
contains anti pZP antibodies, and the serum can be used as a primary, polyclonal antibody during 
Western blot and immunohistochemical analyses. However, since whole serum is being used, 
polyclonal antisera harvested in this way will include not only antibodies to the antigen of 
interest, but also irrelevant antibodies present as part of normal immune function. For this 
reason, polyclonal antibodies are known to have higher affinity and wider reactivity, yet lower 
specificity when compared with monoclonal antibodies (Ramos-Vara 2005). Polyclonal 
antibodies are also more likely to identify multiple isoforms of the target antigen, as well as 
irrelevant proteins that other antibodies present in the serum may be reactive to. (Ramos-Vara 
2005) The ability of polyclonal antibodies to recognize multiple epitopes of the same protein 
partly explains the variability seen during Western blot analysis for zona protein molecular 
weight. For instance, figure 5 shows antibodies in the serum of SpayVac vaccinated mares (5b) 
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and rabbit anti ZP3 polyclonal antibody (5a) binding 2 side-by-side protein samples at slightly 
different molecular weights.  
Furthermore, zona proteins are large glycoproteins with extensive post-translational 
modifications. Heavy glycosylation and sulfation patterns lend to variances in electrophoretic 
mobilities and carbohydrate moieties among and within the protein families and species. This 
results in a range of molecular weights that can be observed for the same protein family (Dunbar 
et al. 1994, Prasad et al. 2000). Adding to the complexity, proteolytic cleavage and 
deglycosylation events have been shown to process the larger zona glycoproteins into smaller 
polypeptides; while zona proteins are also characterized by the tendency to self-assemble into 
matrices and thus exist as heterodimers. (Wassarman 1988, Prasad et al. 2000) These post 
translational modifications complicate the ability to accurately identify zona proteins by 
electrophoresis. Dunbar et al. (1985) and Wassarman (1988) confirm this by identifying a zona 
protein family in the 6-30 kDA range formed by proteolytic processing of the ZP2 protein. 
Similarly, multiple authors note molecular weight ranges for each zona protein, rather than cite a 
specific and consistent size (Dunbar et al. 1985, Wasserman 1988, Miller et al. 1992). The 
authors attribute this variation in molecular weight to differences in post-translational 
modification patterns. Variability in glycosylation level, proteolytic cleavage events, and species 
lends insight into why the same anti ZP3 polyclonal antibody bound in the 15-20 kDA range in 
figure 11 while binding in the 50-75 kDa range in figure 5. Similarly, Western blot analysis 
revealed the binding of antibodies in the serum of SpayVac vaccinated mares to zona protein 
anywhere from 50 kDa (Figure 5b) to 100 kDa (Figure 6b). 
Figures 9 and 10 indicate a specificity of anti pZP antibodies from the serum of SpayVac 
vaccinated mares for equine zona proteins 3 and 4. Likewise, Western blot analyses revealed the 
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binding of anti pZP antibodies to zona proteins in the 37-75 kDa range; indicating an 
immunoreactivity of anti pZP antibodies to the zona proteins that typically reside in this 
molecular range. Nonetheless, it is difficult to conclude that anti pZP antibodies are specific for 
these two zona proteins knowing their tendency to form heterodimers and express varying levels 
of glycosylation. For instance, a polypeptide proteolytically cleaved from ZP2 could form a 
dimer with ZP3 and show up in this 50-75 kDa range. ZP3 itself is also thought to be composed 
of two components which, when exposed to proteases, yields two smaller polypeptides. 
(Wassarman 1988) 
Alternatively, Wasserman (1988) declared ZP3 to be the major component of the porcine 
zona pellucida, representing as much as 70-80% of total protein content. When the pZP antigen 
is isolated, the entire zona pellucida is homogenized, resulting in a compilation of all zona 
protein families. It follows that 70-80% of the pZP antigen is thus accounted for by ZP3, with the 
remaining 20-30% representing the other zona and matrix proteins. When injected with pZP, the 
mare would produce substantially more antibodies against ZP3 than the other proteins. Antisera 
harvested from the mare therefore expresses higher specificity for ZP3 than the other zona 
proteins, and consequently bind ZP3 in Western blot and immunohistochemical analyses more 
prominently.  This explains how pre-incubating the Western blot membrane with anti ZP3 
antibodies blocked the ability of anti pZP antibodies to bind the protein, whereas pre-incubating 
the membrane with anti ZP4 antibodies only attenuated the binding of anti pZP antibodies to the 
protein.  
 Finally, due to the difficulty in obtaining equine samples, the sample size for these 
experiments was limited. When possible, each experiment was performed at least twice to verify 
results and repeatability. While this study was intended as a demonstration of a concept, an 
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increased sample size would have been preferable. Also, individual differences in immune 
response between mares may lead to variations in the quantity and biological ability of 
antibodies produced. Serum samples were selectively chosen from mares of high antibody titer 
level, and while it is generally assumed that titer level has a direct correlation with vaccine 
efficacy, this has yet to be scientifically proven. Similarly, although all nine serum samples used 
contained antibodies immunoreactive to equine zona protein, two of the nine serum samples 
were from SpayVac treated mares that were still able to conceive despite vaccination. A valuable 
control in this study would have been to have serum samples from each mare prior to and 
following vaccination, such that each mare could serve as her own negative control.   
 Collectively, results suggest a model where anti pZP antibodies produced in response to 
SpayVac vaccination are immunoreactive to equine zona proteins under the correct conditions. 
When zona proteins are isolated from equine tissues and made available to serum samples from 
SpayVac vaccinated mares, antibodies in the serum are consistently able to recognize the protein. 
When subjected to the same protocol, antibodies in the serum of non-vaccinated mares did not 
express this immunoreactivity to zona protein. This suggests that the antibodies immunoreactive 
to zona protein in the serum samples of SpayVac vaccinated mares are a result of SpayVac 
vaccination. Furthermore, these antibodies appear to be immunoreactive to zona protein isolated 
from both mature, pre-ovulatory oocytes isolated from graafian follicles as well as immature 
oocytes embedded in ovarian tissue. With that said, this study merely illustrates a pathway by 
which anti pZP antibodies could act if they are biologically available to these tissues under the 
correct conditions. It has yet to be investigated whether anti pZP antibodies are present in the 
follicular fluid of follicles or whether they are able to permeate ovarian tissue and access primary 
follicles following SpayVac vaccination. Similarly, the protein presented to anti pZP antibodies 
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during Western blot and immunohistochemical analysis has been subjected to various processing 
steps, including antigen retrieval, denaturing buffers, and lysis buffers to name a few. These 
steps aid in the unfolding of protein such that binding sites become more available to antibodies. 
In vitro, these proteins will be folded in 3D structures and thus may not be as available for 
antibody binding. This study therefore demonstrates a model by which anti pZP antibodies may 
bind zona proteins, thereby interfering with a critical reproductive event, and ultimately resulting 
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Appendix I: Serum Samples from SpayVac Vaccinated Mares 
 
Assay-HorseID Avg. OD Std. Dev.  % of Std. (Titer) 
27-4131 0.672 0.009 117.28 
24-1729 0.950 0.028 163.79 
13-4133 0.633 0.020 109.08 
28-3799+ 0.721 0.007 125.83 
79-6527 0.586 0.020 97.83 
4-2816 0.826 0.021 142.47 
43-6498 0.771 0.117 134.50 
19-361* 1.034 0.014 178.33 
15-1688**+ 0.230 0.006 39.66 
*Sample with the highest antibody titer 
**Sample with the lowest antibody titer 
+ Mares conceived in 2011 after vaccination and foaled in 2012 
 
 
List of serum samples used from SpayVac vaccinated mares along with relative antibody titer 
levels. Mares were vaccinated on March 31, 2011 in Pauls Valley, Oklahoma with SpayVac and 
serum samples were collected on May 3, 2011. Anti pZP antibody titers from these samples were 
determined by enzyme-linked immunosorbent assay (ELISA) by Immunovaccine Inc. (Halifax, 
Nova Scotia).  Titers were read as average optical density (Avg. OD) and standard deviation 
(Std. Dev.) across 3 readings of the same sample. The samples were then reported as a percent of 
standard (% of Std.), where the standard was a serum sample thought to be of good response to 
the vaccination. The larger the percent of standard column value is, the higher the titer level of 
the individual mare is thought to be.  Assay-HorseID simply refers to the assay number assigned 
to the serum sample followed by the horse number. Of the top 15 samples collected on May 3, 
2011 with the highest titer levels, the above 8 were chosen at random for use. The last sample 















Appendix II: RIPA Lysis Buffer 
RIPA Lysis Buffer is prepared as follows: 
1. Combine: 
150mL ddH2O 
0.484g Tris (pH 8.0) 
1.6 NaCl 
20mL Glycerol 
2mL Nonidet P-40 (NP-40) 
0.2g Sodium Dodecyl Sulfate (SDS) 
1.0g Deoxychlorate 
0.117g Ethylenediamine tetraacetic acid (EDTA) 
2. Allow solvents to dissolve and adjust pH to 8.0 with HCL 

































Appendix III: Western blot Polyacrylamide Gels Preparation 
12% running gel 
1.8mL H2O 
4.0mL 1M Tris (pH 8.8) 
4.0mL Acrylamide 30:0.8 
100μL 10% SDS 
5μL TEMED 
100μL 10% APS 
 
Stacking gel 
 4.2mL H2O 
 0.99mL Acrylamide 
 0.75mL 1M Tris (pH 6.8) 
 60μL 10% SDS 
 15μL TEMED 






























Appendix IV: 6x Sample Buffer Recipe 
50 mL 6x Sample Buffer 
2.363g Tris-HCL (pH 6.8) 
10mL glycerol 
3g SDS 
0.1g Bromo Blue 
Dilute 4:1 with 1M dithiolthreitol (DTT) 
 
































Appendix V: Zona Protein Sequences 












































































Bos taurus ZP4 sequence 
MWLLLQLVWLCFLLSLGLNSWHQSKVPEYPDELRCGLRSFQFTINPLSQETETPPVLVAW 
DNHGLPHSLQNDSDCGTWVSEGPGSSLVGEASYSGCYVTEWESYYIMTVGIERAGVSGSG 
AFIETKLFKCPVNLPDVPNAGLCDSVPVWDRLPCAPSPITQGDCKQLGCCYNSEEVISCY 
YGNTVTSHCTQDGHFSIAVSRNVTSPPLLLNSVHLAFRNDSECKPVMATHTFVLFRFPFT 
TCGTTKQITGKQAVYENELVAARDVRTWSRGSITRDSTFRLQVSCSYSASSSALPVNVQV 
LTLPPPLPETQPGNLTLELKIAKDKRYRSYYTASDYPVVKLLRDPIYVEVSIHQRTDPSL 
ELRLDQCWATPGADALLQPQWPLLVNGCPYTGDNYQTKLIPVWEASDLPFPSHYQRFSIS 
TFSFVDSVAKRALKGPVYLHCSASVCQPAGTPSCVTLCPARRRRSSDIHFQNNTASISSK 
GPLILLQAIQDSSEKLHKYSRSPVDSQALWVAGLSGILIVGALFMSYLAIRKWR 
 
